US20090053705A1 - Methods for increasing accuracy of nucleic acid sequencing - Google Patents

Methods for increasing accuracy of nucleic acid sequencing Download PDF

Info

Publication number
US20090053705A1
US20090053705A1 US11/872,436 US87243607A US2009053705A1 US 20090053705 A1 US20090053705 A1 US 20090053705A1 US 87243607 A US87243607 A US 87243607A US 2009053705 A1 US2009053705 A1 US 2009053705A1
Authority
US
United States
Prior art keywords
template
primer
nucleotide
nucleic acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/872,436
Inventor
Timothy D. Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Standard Biotools Corp
Original Assignee
Helicos BioSciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicos BioSciences Corp filed Critical Helicos BioSciences Corp
Priority to US11/872,436 priority Critical patent/US20090053705A1/en
Assigned to HELICOS BIOSCIENCES CORPORATION reassignment HELICOS BIOSCIENCES CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HARRIS, TIMOTHY D.
Publication of US20090053705A1 publication Critical patent/US20090053705A1/en
Assigned to GENERAL ELECTRIC CAPITAL CORPORATION reassignment GENERAL ELECTRIC CAPITAL CORPORATION SECURITY AGREEMENT Assignors: HELICOS BIOSCIENCES CORPORATION
Assigned to HELICOS BIOSCIENCES CORPORATION reassignment HELICOS BIOSCIENCES CORPORATION RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: GENERAL ELECTRIC CAPITAL CORPORATION
Assigned to FLUIDIGM CORPORATION reassignment FLUIDIGM CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HELICOS BIOSCIENCES CORPORATION
Assigned to PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reassignment PACIFIC BIOSCIENCES OF CALIFORNIA, INC. LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: FLUIDIGM CORPORATION
Assigned to SEQLL, LLC reassignment SEQLL, LLC LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: FLUIDIGM CORPORATION
Assigned to COMPLETE GENOMICS, INC. reassignment COMPLETE GENOMICS, INC. LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: FLUIDIGM CORPORATION
Assigned to ILLUMINA, INC. reassignment ILLUMINA, INC. LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: FLUIDIGM CORPORATION
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • C12Q1/6874Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation

Definitions

  • the invention generally relates to methods for increasing accuracy in nucleic acid synthesis reactions.
  • nucleic acid synthesis is a foundation of many fundamental research and diagnostic tools, such as nucleic acid amplification and sequencing.
  • a nucleic acid polymerase In a template-dependent nucleic acid synthesis reaction, the sequential addition of nucleotides is catalyzed by a nucleic acid polymerase.
  • the nucleic acid polymerase may be a DNA polymerase, an RNA polymerase, or a reverse transcriptase.
  • the accuracy of template-dependent nucleic acid synthesis depends in part on the ability of the polymerase to discriminate between complementary and non-complementary nucleotides. Normally, the conformation of the polymerase enzyme favors incorporation of the complementary nucleotide. However, there is still an identifiable rate of misincorporation that depends upon factors such as local sequence and the base to be incorporated.
  • the reduced efficiency with which the unconventional nucleotides are incorporated by the polymerase can adversely affect the performance of sequencing techniques that depend upon faithful incorporation of such unconventional nucleotides.
  • Single molecule sequencing techniques allow the evaluation of individual nucleic acid molecules in order to identify changes and/or differences affecting genomic function.
  • a nucleic acid fragment is attached to a solid support such that at least a portion of the nucleic acid fragment is individually optically-resolvable. Sequencing is conducted using the fragments as templates. Sequencing events are detected and correlated to the individual strands. See Braslavsky et al., Proc. Natl. Acad. Sci., 100: 3960-64 (2003), incorporated by reference herein. Because single molecule techniques do not rely on ensemble averaging as do bulk techniques, errors due to misincorporation can have a significant deleterious effect on the sequencing results.
  • nucleotide that is incorrectly paired, under standard Watson and Crick base-pairing, with a corresponding template nucleotide during primer extension may result in sequencing errors.
  • misincorporations can have a great impact on the sequence obtained because fewer sequences are obtained with which to compare to each other or with a reference sequence.
  • the invention improves the accuracy of nucleic acid sequencing reactions.
  • a template nucleic acid is hybridized to a primer and template-dependent sequencing-by-synthesis is conducted to extend the 3′ end of the primer.
  • the template is then removed from the extended primer and the primer is then “primed” and re-sequenced.
  • Practice of the invention allows resequencing of the same sequence and its complement in situ, and results in increased accuracy of sequence determination.
  • a polymerization reaction is conducted on a nucleic acid duplex that comprises a primer hybridized to a template nucleic acid.
  • the reaction is conducted in the presence of a polymerase, and at least one nucleotide comprising a detectable label. If the nucleotide is complementary to the next nucleotide in the template, it is added to the primer by the polymerase. The added nucleotide is detected and the reaction is then repeated at least once.
  • the primer is extended by one or more nucleotides corresponding to sequence that is complementary to at least a portion of the template.
  • the template is removed from the duplex, leaving the extended primer.
  • one or more primer/template duplexes are bound to a solid support such that a least some of the duplexes are individually optically detectable.
  • the duplexes are exposed to a polymerase, and at least one detectably-labeled nucleotide under conditions sufficient for template-dependent nucleotide addition to the primer. Unincorporated labeled nucleotides are optionally washed away. The incorporation of the labeled nucleotide is detected, thereby identifying the added nucleotide and the complementary template nucleotide. Base addition, washing, and identification steps can be serially repeated in the presence of detectably labeled nucleotide that corresponds to each of the other nucleotide species. As a result, the primer is extended by the added nucleotides.
  • the added nucleotides correspond to sequence that is complementary to at least a portion of the template.
  • the template is removed from the duplex.
  • the template can be removed by any suitable means, for example by raising the temperature of the surface or the flow cell such that the duplex is melted, or by changing the buffer conditions to destabilize the duplex, or combination thereof. Methods for melting template/primer duplexes are well known in the art and are described, for example, in chapter 10 of Molecular Cloning, a Laboratory Manual, 3 rd Edition, J. Sambrook, and D. W. Russell, Cold Spring Harbor Press (2001), the teachings of which are incorporated herein by reference.
  • the template can then be removed from the surface, for example, by rinsing the surface with a suitable rinsing solution.
  • the extended primer used in the polymerization reaction remains on the surface.
  • the 3′ terminus of the primer is then modified by addition of a short polynucleotide.
  • the polynucleotide is added to the primer by enzymatic catalysis.
  • a preferred enzyme is a ligase or a polymerase.
  • Suitable ligases include, for example, T4 DNA ligase and T4 RNA ligase (such ligases are available commercially, from New England BioLabs (on the World Wide Web at NEB.com) and others capable of adding nucleotides to the 3′ terminus of the primer.
  • a dephosphorylated polynucleotide is added to the primer. Methods for using ligases and dephosphorylating oligonucleotides are well known in the art.
  • any suitable enzyme can be used.
  • a polymerase such as poly(A) polymerase, including yeast poly(A) polymerase, commercially available from USB (on the World Wide Web at USBweb.com), terminal deoxyribonucleotidyl transferase (TdT), and the like are useful.
  • the polymerases can be used according to the manufacturer's instructions.
  • the primer is then used as a template for template-dependent sequencing-by-synthesis as described generally above.
  • the polynucleotide added to the primer is chosen such that it is complementary to a new primer (or at least a portion thereof).
  • the polynucleotide is a homopolymer, such as oligo(dA), and the corresponding primer includes an oligo(dT) sequence.
  • the complementary sequences are of a length suitable for hybridization.
  • the added polynucleotide and its complementary new primer can be about 10 to about 100 nucleotides in length, and preferably about 50 nucleotides in length.
  • the added polynucleotide and new primer can be of the same length or of different lengths. It is routine in the art to adjust primer length and/or oligonucleotide length to optimize hybridization.
  • template-dependent sequencing-by-synthesis is conducted on the primer in the opposite direction of the original sequencing reaction (i.e., toward to surface to which the primer is bound).
  • the “new” extended primer can be melted off, leaving a template having the complementary sequence as the original template for optional resequencing in the 3′ to 5′ direction (i.e., toward the surface).
  • Sequencing and/or resequencing at least a portion of the complement of the original template increases the accuracy of the sequence information obtained from a given template by providing more than one set of sequence information to compare, for example, to a reference sequence.
  • the sequence initially obtained can be compared to the sequence obtained from the new template.
  • Sequencing methods of the invention preferably comprise template/primer duplex attached to a surface.
  • Individual nucleotides added to the surface comprise a detectable label—preferably an optically-detectable label, such as a fluorescent label.
  • Each nucleotide species can comprise a different label, or can comprise the same label.
  • each duplex is individually optically resolvable in order to facilitate single molecule sequence discrimination.
  • the choice of a surface for attachment of duplex depends upon the detection method employed.
  • Preferred surfaces for methods of the invention include epoxide surfaces and polyelectrolyte multilayer surfaces, such as those described in Braslavsky, et al., supra. Surfaces preferably are deposited on a substrate that is amenable to optical detection of the surface chemistry, such as glass or silica.
  • Nucleotides useful in the invention include any nucleotide or nucleotide analog, whether naturally-occurring or synthetic.
  • preferred nucleotides include phosphate esters of deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, adenosine, cytidine, guanosine, and uridine.
  • Polymerases useful in the invention include any nucleic acid polymerase capable of catalyzing a template-dependent addition of a nucleotide or nucleotide analog to a primer.
  • a DNA polymerase an RNA polymerase, a reverse transcriptase, or a mutant or altered form of any of the foregoing can be used.
  • a thermophilic polymerase is used, such as ThermoSequenase®, 9°NTM, TherminatorTM, Taq, Tne, Tma, Pfu, Tfl, Tth, Tli, Stoffel fragment, VentTM and Deep VentTM DNA polymerase.
  • FIGURE shows a schematic representation of one embodiment of the present invention.
  • the invention provides methods and compositions for improving the accuracy of nucleic acid sequencing-by-synthesis reactions by re-sequencing a least a portion of a template nucleic acid. While applicable to bulk sequencing methods, the invention is particularly useful in connection with single molecule sequencing methods. According to the invention, the methods comprise the steps of exposing a duplex comprising a template and a primer to a polymerase and one or more nucleotide comprising a detectable label under conditions sufficient for template-dependent nucleotide addition to the primer.
  • the template is individually optically resolvable. Any unincorporated labeled nucleotide is optionally washed way.
  • any nucleotide incorporated into the primer is identified by detecting the label associated with the incorporated nucleotide.
  • the steps of exposing duplex to polymerase and another nucleotide comprising a detectable label and polymerizing, optional washing, and identification are repeated, thereby determining a nucleotide sequence.
  • the primer is extended by the addition of one or more nucleotides that are complementary to the corresponding positions of the template.
  • the template is then removed from the duplex, leaving the extended primer.
  • a polynucleotide is added to the 3′ terminus of the primer or extended primer, thereby forming a modified primer.
  • the modified primer is used as the template in subsequent sequencing reactions.
  • the FIGURE is a schematic representation of one embodiment of the invention.
  • a primer, 2 is attached to a solid support, 3.
  • a template, 1, is hybridized to the primer, forming a template/primer duplex.
  • the template primer/duplex is exposed to a polymerase and at least one nucleotide comprising a detectable label, under conditions sufficient for template-dependent nucleotide addition to said primer. If the nucleotide is complementary to the template nucleotide immediately downstream of the primer, a nucleotide is added to the primer. After identifying nucleotide incorporated into the primer, the process is repeated, thereby adding a second nucleotide to the primer in a template dependent manner, and so on.
  • template complementary sequence, 4 is added to the primer.
  • the template is removed as shown in step B, leaving the extended primer.
  • a polynucleotide, 6, is added to the extended primer at the 3′ terminus (e.g., downstream of the previously added template complementary sequence) forming a new template for sequencing in the opposite direction.
  • a primer capable of hybridizing to the polynucleotide is added, forming a template/primer duplex, 7.
  • step E The process of adding nucleotide and polymerase, detecting incorporated nucleotide and repeating the desired number of times is then repeated using the modified extended primer as a template, as shown in step E, thereby sequencing the template complementary sequence 4, 8.
  • the primer, 6, is extended by the addition of sequence 8 that corresponds to at least a portion of the original template, 1.
  • the extended primer (6, 8) can be removed, F, and the template can be resequenced, as described above.
  • direct amine attachment is used to attach primer or template to an epoxide surface.
  • the primer or the template can comprise an optically-detectable label in order to determine the location of duplex on the surface. At least a portion of the duplex is optically resolvable from other duplexes on the surface.
  • the surface is preferably passivated with a reagent that occupies portions of the surface that might, absent passivation, fluoresce.
  • Optimal passivation reagents include amines, phosphate, water, sulfates, detergents, and other reagents that reduce native or accumulating surface fluorescence.
  • Sequencing is then accomplished by presenting one or more labeled nucleotide in the presence of a polymerase under conditions that promote complementary base incorporation in the primer.
  • a polymerase under conditions that promote complementary base incorporation in the primer.
  • one base at a time is added and all bases have the same label.
  • There is a wash step after each incorporation cycle and the label is either neutralized without removal or removed from incorporated nucleotides.
  • the linear sequence data for each individual duplex is compiled. Numerous algorithms are available for sequence compilation and alignment as discussed below.
  • epoxide-coated glass surfaces are used for direct amine attachment of templates, primers, or both. Amine attachment to the termini of template and primer molecules is accomplished using terminal transferase. Primer molecules can be custom-synthesized to hybridize to templates for duplex formation.
  • a full-cycle is conducted as many times as necessary to complete sequencing of a desired length of template, or resequencing of the desired length of the template complementary sequence. Once the desired number of cycles is complete, the result is a stack of images represented in a computer database. For each spot on the surface that contained an initial individual duplex, there will be a series of light and dark image coordinates, corresponding to whether a base was incorporated in any given cycle.
  • the duplex would be “dark” (i.e., no detectable signal) for the first cycle (presentation of C), but would show signal in the second cycle (presentation of A, which is complementary to the first T in the template sequence).
  • the same duplex would produce signal upon presentation of the G, as that nucleotide is complementary to the next available base in the template, C.
  • the duplex Upon the next cycle (presentation of U), the duplex would be dark, as the next base in the template is G.
  • the sequence of the template would be built up through the image stack. The sequencing data are then fed into an aligner as described below for resequencing, or are compiled for de novo sequencing as the linear order of nucleotides incorporated into the primer.
  • the imaging system used in practice of the invention can be any system that provides sufficient illumination of the sequencing surface at a magnification such that single fluorescent molecules can be resolved.
  • Nucleic acid templates include deoxyribonucleic acid (DNA) and/or ribonucleic acid (RNA).
  • Nucleic acid template molecules can be isolated from a biological sample containing a variety of other components, such as proteins, lipids and non-template nucleic acids.
  • Nucleic acid template molecules can be obtained from any cellular material, obtained from an animal, plant, bacterium, fungus, or any other cellular organism.
  • Biological samples for use in the invention also include viral particles or samples prepared from viral material.
  • Nucleic acid template molecules may be obtained directly from an organism or from a biological sample obtained from an organism, e.g., from blood, urine, cerebrospinal fluid, seminal fluid, saliva, sputum, stool and tissue.
  • Nucleic acid template molecules may also be isolated from cultured cells, such as a primary cell culture or a cell line.
  • the cells or tissues from which template nucleic acids are obtained can be infected with a virus or other intracellular pathogen.
  • a sample can also be total RNA extracted from a biological specimen, a cDNA library, viral, or genomic DNA.
  • Nucleic acid obtained from biological samples typically is fragmented to produce suitable fragments for analysis.
  • nucleic acid from a biological sample is fragmented by sonication.
  • Nucleic acid template molecules can be obtained as described in U.S. Patent Application 2002/0190663 A1, published Oct. 9, 2003, the teachings of which are incorporated herein in their entirety.
  • nucleic acid can be extracted from a biological sample by a variety of techniques such as those described by Maniatis, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y., pp. 280-281 (1982).
  • individual nucleic acid template molecules can be from about 5 bases to about 20 kb.
  • Nucleic acid molecules may be single-stranded, double-stranded, or double-stranded with single-stranded regions (for example, stem- and loop-structures).
  • a biological sample as described herein may be homogenized or fractionated in the presence of a detergent or surfactant.
  • concentration of the detergent in the buffer may be about 0.05% to about 10.0%.
  • concentration of the detergent can be up to an amount where the detergent remains soluble in the solution. In a preferred embodiment, the concentration of the detergent is between 0.1% to about 2%.
  • the detergent particularly a mild one that is nondenaturing, can act to solubilize the sample.
  • Detergents may be ionic or nonionic.
  • ionic detergents examples include deoxycholate, sodium dodecyl sulfate (SDS), N-lauroylsarcosine, and cetyltrimethylammoniumbromide (CTAB).
  • a zwitterionic reagent may also be used in the purification schemes of the present invention, such as Chaps, zwitterion 3-14, and 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulf-onate. It is contemplated also that urea may be added with or without another detergent or surfactant.
  • Lysis or homogenization solutions may further contain other agents, such as reducing agents.
  • reducing agents include dithiothreitol (DTT), ⁇ -mercaptoethanol, DTE, GSH, cysteine, cysteamine, tricarboxyethyl phosphine (TCEP), or salts of sulfurous acid.
  • Nucleotides useful in the invention include any nucleotide or nucleotide analog, whether naturally-occurring or synthetic.
  • preferred nucleotides include phosphate esters of deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, adeno sine, cytidine, guano sine, and uridine.
  • nucleotides useful in the invention comprise an adenine, cytosine, guanine, thymine base, a xanthine or hypoxanthine; 5-bromouracil, 2-aminopurine, deoxyinosine, or methylated cytosine, such as 5-methylcytosine, and N4-methoxydeoxycytosine.
  • bases of polynucleotide mimetics such as methylated nucleic acids, e.g., 2′-O-methRNA, peptide nucleic acids, modified peptide nucleic acids, locked nucleic acids and any other structural moiety that can act substantially like a nucleotide or base, for example, by exhibiting base-complementarity with one or more bases that occur in DNA or RNA and/or being capable of base-complementary incorporation, and includes chain-terminating analogs.
  • a nucleotide corresponds to a specific nucleotide species if they share base-complementarity with respect to at least one base.
  • Nucleotides for nucleic acid sequencing according to the invention preferably comprise a detectable label that is directly or indirectly detectable.
  • Preferred labels include optically-detectable labels, such as fluorescent labels.
  • fluorescent labels include, but are not limited to, 4-acetamido-4′-isothiocyanatostilbene-2,2′disulfonic acid; acridine and derivatives: acridine, acridine isothiocyanate; 5-(2′-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS); 4-amino-N-[3-vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate; N-(4-anilino-1-naphthyl)maleimide; anthranilamide; BODIPY; Brilliant Yellow; coumarin and derivatives; coumarin, 7-amino-4-methylcoumarin (AMC, Coumarin 120), 7
  • Nucleic acid polymerases generally useful in the invention include DNA polymerases, RNA polymerases, reverse transcriptases, and mutant or altered forms of any of the foregoing. DNA polymerases and their properties are described in detail in, among other places, DNA Replication 2nd edition, Komberg and Baker, W. H. Freeman, New York, N.Y. (1991).
  • Known conventional DNA polymerases useful in the invention include, but are not limited to, Pyrococcus furiosus (Pfu) DNA polymerase (Lundberg et al., 1991, Gene, 108: 1, Stratagene), Pyrococcus woesei (Pwo) DNA polymerase (Hinnisdaels et al., 1996, Biotechniques, 20:186-8, Boehringer Mannheim), Thermus thermophilus (Tth) DNA polymerase (Myers and Gelfand 1991, Biochemistry 30:7661), Bacillus stearothermophilus DNA polymerase (Stenesh and McGowan, 1977, Biochim Biophys Acta 475:32), Thermococcus litoralis (Tli) DNA polymerase (also referred to as VentTM DNA polymerase, Cariello et al., 1991, Polynucleotides Res, 19: 4193, New England Biolabs), 9°NmTM DNA polymerase (New England Biolabs),
  • thermococcus sp Thermus aquaticus (Taq) DNA polymerase (Chien et al., 1976, J. Bacteoriol, 127: 1550), DNA polymerase, Pyrococcus kodakaraensis KOD DNA polymerase (Takagi et al., 1997, Appl. Environ. Microbiol. 63:4504), JDF-3 DNA polymerase (from thermococcus sp.
  • Thermophilic DNA polymerases include, but are not limited to, ThermoSequenase®, 9°NTM, TherminatorTM, Taq, Tne, Tma, Pfu, Tfl, Tth, Tli, Stoffel fragment, VentTM and Deep VentTM DNA polymerase, KOD DNA polymerase, Tgo, JDF-3, and mutants, variants and derivatives thereof.
  • Reverse transcriptases useful in the invention include, but are not limited to, reverse transcriptases from HIV, HTLV-1, HTLV-II, FeLV, FIV, SIV, AMV, MMTV, MoMuLV and other retroviruses (see Levin, Cell 88:5-8 (1997); Verma, Biochim Biophys Acta. 473:1-38 (1977); Wu et al., CRC Crit Rev Biochem. 3:289-347 (1975)).
  • nucleic acid template molecules are attached to a substrate (also referred to herein as a surface) and subjected to analysis by sequencing as taught herein. Nucleic acid template molecules are attached to the surface such that the template/primer duplexes are individually optically resolvable.
  • Substrates for use in the invention can be two- or three-dimensional and can comprise a planar surface (e.g., a glass slide) or can be shaped.
  • a substrate can include glass (e.g., controlled pore glass (CPG)), quartz, plastic (such as polystyrene (low cross-linked and high cross-linked polystyrene), polycarbonate, polypropylene and poly(methymethacrylate)), acrylic copolymer, polyamide, silicon, metal (e.g., alkanethiolate-derivatized gold), cellulose, nylon, latex, dextran, gel matrix (e.g., silica gel), polyacrolein, or composites.
  • CPG controlled pore glass
  • plastic such as polystyrene (low cross-linked and high cross-linked polystyrene), polycarbonate, polypropylene and poly(methymethacrylate)
  • acrylic copolymer polyamide
  • silicon e.g., metal (e.g., alkanethiolate-derivatized gold)
  • cellulose e.g., nylon, latex, dextran, gel matrix (e.g.
  • Suitable three-dimensional substrates include, for example, spheres, microparticles, beads, membranes, slides, plates, micromachined chips, tubes (e.g., capillary tubes), microwells, microfluidic devices, channels, filters, or any other structure suitable for anchoring a nucleic acid.
  • Substrates can include planar arrays or matrices capable of having regions that include populations of template nucleic acids or primers. Examples include nucleoside-derivatized CPG and polystyrene slides; derivatized magnetic slides; polystyrene grafted with polyethylene glycol, and the like.
  • a substrate is coated to allow optimum optical processing and nucleic acid attachment.
  • Substrates for use in the invention can also be treated to reduce background.
  • Exemplary coatings include epoxides, and derivatized epoxides (e.g., with a binding molecule, such as streptavidin).
  • the surface can also be treated to improve the positioning of attached nucleic acids (e.g., nucleic acid template molecules, primers, or template molecule/primer duplexes) for analysis.
  • a surface according to the invention can be treated with one or more charge layers (e.g., a negative charge) to repel a charged molecule (e.g., a negatively charged labeled nucleotide).
  • a substrate according to the invention can be treated with polyallylamine followed by polyacrylic acid to form a polyelectrolyte multilayer.
  • the carboxyl groups of the polyacrylic acid layer are negatively charged and thus repel negatively charged labeled nucleotides, improving the positioning of the label for detection.
  • Coatings or films applied to the substrate should be able to withstand subsequent treatment steps (e.g., photoexposure, boiling, baking, soaking in warm detergent-containing liquids, and the like) without substantial degradation or disassociation from the substrate.
  • substrate coatings include, vapor phase coatings of 3-aminopropyltrimethoxysilane, as applied to glass slide products, for example, from Molecular Dynamics, Sunnyvale, Calif.
  • hydrophobic substrate coatings and films aid in the uniform distribution of hydrophilic molecules on the substrate surfaces.
  • the coatings or films that are substantially non-interfering with primer extension and detection steps are preferred.
  • any coatings or films applied to the substrates either increase template molecule binding to the substrate or, at least, do not substantially impair template binding.
  • Various methods can be used to anchor or immobilize the primer to the surface of the substrate.
  • the immobilization can be achieved through direct or indirect bonding to the surface.
  • the bonding can be by covalent linkage. See, Joos et al., Analytical Biochemistry 247:96-101, 1997; Oroskar et al., Clin. Chem. 42:1547-1555, 1996; and Khandjian, Mol. Bio. Rep. 11:107-115, 1986.
  • a preferred attachment is direct amine bonding of a terminal nucleotide of the template or the primer to an epoxide integrated on the surface.
  • the bonding also can be through non-covalent linkage.
  • biotin-streptavidin (Taylor et al., J. Phys. D. Appl. Phys. 24:1443, 1991) and digoxigenin with anti-digoxigenin (Smith et al., Science 253:1122, 1992) are common tools for anchoring nucleic acids to surfaces and parallels.
  • the attachment can be achieved by anchoring a hydrophobic chain into a lipid monolayer or bilayer.
  • Other methods for known in the art for attaching nucleic acid molecules to substrates also can be used.
  • exemplary detection methods include radioactive detection, optical absorbance detection, e.g., UV-visible absorbance detection, optical emission detection, e.g., fluorescence or chemiluminescence.
  • extended primers can be detected on a substrate by scanning all or portions of each substrate simultaneously or serially, depending on the scanning method used.
  • fluorescence labeling selected regions on a substrate may be serially scanned one-by-one or row-by-row using a fluorescence microscope apparatus, such as described in Fodor (U.S. Pat. No. 5,445,934) and Mathies et al. (U.S. Pat. No. 5,091,652).
  • Devices capable of sensing fluorescence from a single molecule include scanning tunneling microscope (siM) and the atomic force microscope (AFM). Hybridization patterns may also be scanned using a CCD camera (e.g., Model TE/CCD512SF, Princeton Instruments, Trenton, N.J.) with suitable optics (Ploem, in Fluorescent and Luminescent Probes for Biological Activity Mason, T. G. Ed., Academic Press, Landon, pp. 1-11 (1993), such as described in Yershov et al., Proc. Natl. Aca. Sci. 93:4913 (1996), or may be imaged by TV monitoring.
  • CCD camera e.g., Model TE/CCD512SF, Princeton Instruments, Trenton, N.J.
  • suitable optics Ploem, in Fluorescent and Luminescent Probes for Biological Activity Mason, T. G. Ed., Academic Press, Landon, pp. 1-11 (1993), such as described in Yers
  • a phosphorimager device For radioactive signals, a phosphorimager device can be used (Johnston et al., Electrophoresis, 13:566, 1990; Drmanac et al., Electrophoresis, 13:566, 1992; 1993).
  • Other commercial suppliers of imaging instruments include General Scanning Inc., (Watertown, Mass. on the World Wide Web at genscan.com), Genix Technologies (Waterloo, Ontario, Canada; on the World Wide Web at confocal.com), and Applied Precision Inc. Such detection methods are particularly useful to achieve simultaneous scanning of multiple attached template nucleic acids.
  • Optical setups include near-field scanning microscopy, far-field confocal microscopy, wide-field epi-illumination, light scattering, dark field microscopy, photoconversion, single and/or multiphoton excitation, spectral wavelength discrimination, fluorophore identification, evanescent wave illumination, and total internal reflection fluorescence (TIRF) microscopy.
  • TIRF total internal reflection fluorescence
  • certain methods involve detection of laser-activated fluorescence using a microscope equipped with a camera.
  • Suitable photon detection systems include, but are not limited to, photodiodes and intensified CCD cameras.
  • an intensified charge couple device (ICCD) camera can be used.
  • ICCD intensified charge couple device
  • the use of an ICCD camera to image individual fluorescent dye molecules in a fluid near a surface provides numerous advantages. For example, with an ICCD optical setup, it is possible to acquire a sequence of images (movies) of fluorophores.
  • TIRF microscopy uses totally internally reflected excitation light and is well known in the art. See, e.g., the World Wide Web at nikon-instrumentsjp/eng/page/products/tirf.aspx.
  • detection is carried out using evanescent wave illumination and total internal reflection fluorescence microscopy.
  • An evanescent light field can be set up at the surface, for example, to image fluorescently-labeled nucleic acid molecules.
  • the optical field does not end abruptly at the reflective interface, but its intensity falls off exponentially with distance.
  • This surface electromagnetic field called the “evanescent wave”
  • the thin evanescent optical field at the interface provides low background and facilitates the detection of single molecules with high signal-to-noise ratio at visible wavelengths.
  • the evanescent field also can image fluorescently-labeled nucleotides upon their incorporation into the attached template/primer complex in the presence of a polymerase. Total internal reflectance fluorescence microscopy is then used to visualize the attached template/primer duplex and/or the incorporated nucleotides with single molecule resolution.
  • Alignment and/or compilation of sequence results obtained from the image stacks produced as generally described above utilizes look-up tables that take into account possible sequences changes (due, e.g., to errors, mutations, etc.). Essentially, sequencing results obtained as described herein are compared to a look-up type table that contains all possible reference sequences plus 1 or 2 base errors.
  • a preferred embodiment for sequence alignment compares sequences obtained to a database of reference sequences of the same length, or within 1 or 2 bases of the same length, from the initially obtained sequence or the target sequence contained in a look-up table format.
  • the look-up table contains exact matches with respect to the reference sequence and sequences of the prescribed length or lengths that have one or two errors (e.g., 9-mers with all possible 1-base or 2-base errors).
  • the obtained sequences are then matched to the sequences on the look-up table and given a score that reflects the uniqueness of the match to sequence(s) in the table.
  • the obtained sequences are then aligned to the reference sequence based upon the position at which the obtained sequence best matches a portion of the reference sequence. More detail on the alignment process is provided below in the Example.
  • the 7249 nucleotide genome of the bacteriophage M13mp18 was sequenced using single molecule methods of the invention.
  • Purified, single-stranded viral M13mp18 genomic DNA was obtained from New England Biolabs. Approximately 25 ug of M13 DNA was digested to an average fragment size of 40 bp with 0.1 U Dnase I (New England Biolabs) for 10 minutes at 37° C. Digested DNA fragment sizes were estimated by running an aliquot of the digestion mixture on a precast denaturing (TBE-Urea) 10% polyacrylamide gel (Novagen) and staining with SYBR Gold (Invitrogen/Molecular Probes).
  • the DNase I-digested genomic DNA was filtered through a YM10 ultrafiltration spin column (Millipore) to remove small digestion products less than about 30 nt. Approximately 20 pmol of the filtered DNase I digest was then polyadenylated with terminal transferase according to known methods (Roychoudhury, R and Wu, R. 1980, Terminal transferase-catalyzed addition of nucleotides to the 3′ termini of DNA. Methods Enzymol. 65(1):43-62.). The average dA tail length was 50+/ ⁇ 5 nucleotides. Terminal transferase was then used to label the fragments with Cy3-dUTP.
  • Epoxide-coated glass slides were prepared for oligo attachment. Epoxide-functionalized 40 mm diameter #1.5 glass cover slips (slides) were obtained from Erie Scientific (Salem, N.H.). The slides were preconditioned by soaking in 3 ⁇ SSC for 15 minutes at 37° C. Next, a 500 pM aliquot of 5′ aminated polydT(50) primer (polythymidine of 50 nucleotides in length with a 5′ terminal amine) is incubated with each slide for 30 minutes at room temperature in a volume of 80 ml. The resulting slides have primer attached by direct amine linkage to the epoxide.
  • 5′ aminated polydT(50) primer polythymidine of 50 nucleotides in length with a 5′ terminal amine
  • slides are then treated with phosphate (1 M) for 4 hours at room temperature in order to passivate the surface.
  • Slides re then stored in polymerase rinse buffer (20 mM Tris, 100 mM NaCl, 0.001% Triton X-100, pH 8.0) until they are used for sequencing.
  • the slides are placed in a modified FCS2 flow cell (Bioptechs, Butler, Pa.) using a 50 um thick gasket
  • the flow cell is placed on a movable stage that is part of a high-efficiency fluorescence imaging system built around a Nikon TE-2000 inverted microscope equipped with a total internal reflection (TIR) objective.
  • the slide is then rinsed with HEPES buffer with 100 mM NaCl and equilibrated to a temperature of 50° C.
  • An aliquot of poly(dT50) template is placed in the flow cell and incubated on the slide for 15 minutes.
  • the flow cell is rinsed with 1 ⁇ SSC/HEPES/0.1% SDS followed by HEPES/NaCl.
  • a passive vacuum apparatus is used to pull fluid across the flow cell.
  • the resulting slide contains M13 template/primer duplex.
  • the temperature of the flow cell is then reduced to 37° C. for sequencing and the objective is brought into contact with the flow cell.
  • cytosine triphosphate, guanidine triphosphate, adenine triphosphate, and uracil triphosphate each having a cyanine-5 label (at the 7-deaza position for ATP and GTP and at the C5 position for CTP and UTP (PerkinElmer)) are stored separately in buffer containing 20 mM Tris-HCl, pH 8.8, 10 mM MgSO 4 , 10 mM (NH 4 ) 2 SO 4 , 10 mM HCl, and 0.1% Triton X-100, and 100 U Klenow exo ⁇ polymerase (NEN). Sequencing proceeds as follows.
  • initial imaging is used to determine the positions of duplex on the epoxide surface.
  • the Cy3 label attached to the M13 templates is imaged by excitation using a laser tuned to 532 nm radiation (Verdi V-2 Laser, Coherent, Inc., Santa Clara, Calif.) in order to establish duplex position. For each slide only single fluorescent molecules imaged in this step are counted. Imaging of incorporated nucleotides as described below is accomplished by excitation of a cyanine-5 dye using a 635 nm radiation laser (Coherent). 5 uM Cy5CTP is placed into the flow cell and exposed to the slide for 2 minutes.
  • SSC/HEPES/SDS 1 ⁇ SSC/15 mM HEPES/0.1% SDS/pH 7.0
  • HEPES/NaCl 150 mM HEPES/150 mM NaCl/pH 7.0
  • An oxygen scavenger containing 30% acetonitrile and scavenger buffer (134 ul HEPES/NaCl, 24 ul 100 mM Trolox in MES, pH6.1, 10 ul DABCO in MES, pH6.1, 8 ul 2M glucose, 20 ul NaI (50 mM stock in water), and 4 ul glucose oxidase) is next added.
  • the slide is then imaged (500 frames) for 0.2 seconds using an Inova301K laser (Coherent) at 647 nm, followed by green imaging with a Verdi V-2 laser (Coherent) at 532 nm for 2 seconds to confirm duplex position. The positions having detectable fluorescence are recorded.
  • the flow cell is rinsed 5 times each with SSC/HEPES/SDS (60 ul) and HEPES/NaCl (60 ul).
  • the cyanine-5 label is cleaved off incorporated CTP by introduction into the flow cell of 50 mM TCEP for 5 minutes, after which the flow cell is rinsed 5 times each with SSC/HEPES/SDS (60 ul) and HEPES/NaCl (60 ul).
  • the remaining nucleotide is capped with 50 mM iodoacetamide for 5 minutes followed by rinsing 5 times each with SSC/HEPES/SDS (60 ul) and HEPES/NaCl (60 ul).
  • the scavenger is applied again in the manner described above, and the slide is again imaged to determine the effectiveness of the cleave/cap steps and to identify non-incorporated fluorescent objects.
  • the image stack data i.e., the single molecule sequences obtained from the various surface-bound duplex
  • the image data obtained can be compressed to collapse homopolymeric regions.
  • sequence “TCAAAGC” is represented as “TCAGC” in the data tags used for alignment.
  • homopolymeric regions in the reference sequence are collapsed for alignment.
  • the alignment algorithm matches sequences obtained as described above with the actual M13 linear sequence. Placement of obtained sequence on M13 is based upon the best match between the obtained sequence and a portion of M13 of the same length, taking into consideration 0, 1, or 2 possible errors. All obtained 9-mers with 0 errors (meaning that they exactly match a 9-mer in the M13 reference sequence) are first aligned with M13. Then 10-, 11-, and 12-mers with 0 or 1 error are aligned. Finally, all 13-mers or greater with 0, 1, or 2 errors are aligned.
  • the template fragments are removed by increasing the temperature of the flow cell above the melting temperature of the duplex, thereby releasing the template fragments from the duplexes.
  • the free templates are removed from the flow cell by washing the flow cell, for example the flow cell can be rinsed 5 times each with SSC/HEPES/SDS (60 ul) and HEPES/NaCl (60 ul).
  • the primers are then modified by adding a polynucleotide sequence to the 3′ terminus of the primer.
  • the oligonucleotide-modified primers are then used as the template in subsequent polymerization reactions.
  • Free primer capable of hybridizing to the added oligonucleotide is added to the flow cell and incubated under conditions sufficient to allow hybridization between the added oligonucleotide portion of the template and the free primer. After incubation, the flow cell is rinsed with 1 ⁇ SSC/HEPES/0.1% SDS followed by HEPES/NaCl.
  • the resulting slide contains template/primer duplexes where the template comprises the original primer having M13 template complementary sequences added thereto and modified with an oligonucleotide.
  • the temperature of the flow cell is then reduced to 37° C. for sequencing and the objective is brought into contact with the flow cell.
  • the procedure (expose to nucleotide, polymerase, rinse, scavenger, image, rinse, cleave, rinse, cap, rinse, scavenger, final image) is repeated as described above.
  • the image stack data i.e., the single molecule sequences obtained from the various surface-bound duplex
  • the image data obtained can be compressed to collapse homopolymeric regions as described above.

Abstract

The invention provides methods for improving the accuracy of a sequencing-by-synthesis reaction by sequencing at least a portion of a template and at least a portion of template complementary sequence.

Description

    TECHNICAL FIELD OF THE INVENTION
  • The invention generally relates to methods for increasing accuracy in nucleic acid synthesis reactions.
  • BACKGROUND OF THE INVENTION
  • In vitro nucleic acid synthesis is a foundation of many fundamental research and diagnostic tools, such as nucleic acid amplification and sequencing. In a template-dependent nucleic acid synthesis reaction, the sequential addition of nucleotides is catalyzed by a nucleic acid polymerase. Depending on the template and the nature of the reaction, the nucleic acid polymerase may be a DNA polymerase, an RNA polymerase, or a reverse transcriptase.
  • The accuracy of template-dependent nucleic acid synthesis depends in part on the ability of the polymerase to discriminate between complementary and non-complementary nucleotides. Normally, the conformation of the polymerase enzyme favors incorporation of the complementary nucleotide. However, there is still an identifiable rate of misincorporation that depends upon factors such as local sequence and the base to be incorporated.
  • Synthetic or modified nucleotides and analogs, such as labeled nucleotides, tend to be incorporated into a primer less efficiently than naturally-occurring nucleotides. The reduced efficiency with which the unconventional nucleotides are incorporated by the polymerase can adversely affect the performance of sequencing techniques that depend upon faithful incorporation of such unconventional nucleotides.
  • Single molecule sequencing techniques allow the evaluation of individual nucleic acid molecules in order to identify changes and/or differences affecting genomic function. In single molecule techniques, a nucleic acid fragment is attached to a solid support such that at least a portion of the nucleic acid fragment is individually optically-resolvable. Sequencing is conducted using the fragments as templates. Sequencing events are detected and correlated to the individual strands. See Braslavsky et al., Proc. Natl. Acad. Sci., 100: 3960-64 (2003), incorporated by reference herein. Because single molecule techniques do not rely on ensemble averaging as do bulk techniques, errors due to misincorporation can have a significant deleterious effect on the sequencing results. The incorporation of a nucleotide that is incorrectly paired, under standard Watson and Crick base-pairing, with a corresponding template nucleotide during primer extension may result in sequencing errors. Furthermore, where the template being sequenced is present in only one or a few copies in the sample (a rare template), misincorporations can have a great impact on the sequence obtained because fewer sequences are obtained with which to compare to each other or with a reference sequence.
  • There is, therefore, a need in the art for improved methods for improving the accuracy of nucleic acid synthesis reactions, especially in single molecule sequencing.
  • SUMMARY OF THE INVENTION
  • The invention improves the accuracy of nucleic acid sequencing reactions. According to the invention, a template nucleic acid is hybridized to a primer and template-dependent sequencing-by-synthesis is conducted to extend the 3′ end of the primer. The template is then removed from the extended primer and the primer is then “primed” and re-sequenced. Practice of the invention allows resequencing of the same sequence and its complement in situ, and results in increased accuracy of sequence determination.
  • According to the invention, a polymerization reaction is conducted on a nucleic acid duplex that comprises a primer hybridized to a template nucleic acid. The reaction is conducted in the presence of a polymerase, and at least one nucleotide comprising a detectable label. If the nucleotide is complementary to the next nucleotide in the template, it is added to the primer by the polymerase. The added nucleotide is detected and the reaction is then repeated at least once. Thus, the primer is extended by one or more nucleotides corresponding to sequence that is complementary to at least a portion of the template. The template is removed from the duplex, leaving the extended primer.
  • In one embodiment, one or more primer/template duplexes are bound to a solid support such that a least some of the duplexes are individually optically detectable. The duplexes are exposed to a polymerase, and at least one detectably-labeled nucleotide under conditions sufficient for template-dependent nucleotide addition to the primer. Unincorporated labeled nucleotides are optionally washed away. The incorporation of the labeled nucleotide is detected, thereby identifying the added nucleotide and the complementary template nucleotide. Base addition, washing, and identification steps can be serially repeated in the presence of detectably labeled nucleotide that corresponds to each of the other nucleotide species. As a result, the primer is extended by the added nucleotides. The added nucleotides correspond to sequence that is complementary to at least a portion of the template.
  • After one or more primer extension steps, the template is removed from the duplex. The template can be removed by any suitable means, for example by raising the temperature of the surface or the flow cell such that the duplex is melted, or by changing the buffer conditions to destabilize the duplex, or combination thereof. Methods for melting template/primer duplexes are well known in the art and are described, for example, in chapter 10 of Molecular Cloning, a Laboratory Manual, 3rd Edition, J. Sambrook, and D. W. Russell, Cold Spring Harbor Press (2001), the teachings of which are incorporated herein by reference. The template can then be removed from the surface, for example, by rinsing the surface with a suitable rinsing solution.
  • After removing the template, the extended primer used in the polymerization reaction remains on the surface. The 3′ terminus of the primer is then modified by addition of a short polynucleotide. The polynucleotide is added to the primer by enzymatic catalysis. A preferred enzyme is a ligase or a polymerase. Suitable ligases include, for example, T4 DNA ligase and T4 RNA ligase (such ligases are available commercially, from New England BioLabs (on the World Wide Web at NEB.com) and others capable of adding nucleotides to the 3′ terminus of the primer. In a preferred embodiment, a dephosphorylated polynucleotide is added to the primer. Methods for using ligases and dephosphorylating oligonucleotides are well known in the art.
  • If polymerization is used to add polynucleotides to the 3′ terminus of the primer, any suitable enzyme can be used. For example, a polymerase, such as poly(A) polymerase, including yeast poly(A) polymerase, commercially available from USB (on the World Wide Web at USBweb.com), terminal deoxyribonucleotidyl transferase (TdT), and the like are useful. The polymerases can be used according to the manufacturer's instructions.
  • Having been modified as described above, the primer is then used as a template for template-dependent sequencing-by-synthesis as described generally above.
  • The polynucleotide added to the primer is chosen such that it is complementary to a new primer (or at least a portion thereof). In a preferred embodiment, the polynucleotide is a homopolymer, such as oligo(dA), and the corresponding primer includes an oligo(dT) sequence. The complementary sequences are of a length suitable for hybridization. The added polynucleotide and its complementary new primer can be about 10 to about 100 nucleotides in length, and preferably about 50 nucleotides in length. The added polynucleotide and new primer can be of the same length or of different lengths. It is routine in the art to adjust primer length and/or oligonucleotide length to optimize hybridization.
  • Once a polynucleotide is added to the 3′ end of the primer and a new primer sequence is hybridized to the polynucleotide (or portion thereof), template-dependent sequencing-by-synthesis is conducted on the primer in the opposite direction of the original sequencing reaction (i.e., toward to surface to which the primer is bound).
  • After conducting the sequencing reaction back toward to the surface, the “new” extended primer can be melted off, leaving a template having the complementary sequence as the original template for optional resequencing in the 3′ to 5′ direction (i.e., toward the surface).
  • Sequencing and/or resequencing at least a portion of the complement of the original template increases the accuracy of the sequence information obtained from a given template by providing more than one set of sequence information to compare, for example, to a reference sequence. In another embodiment, the sequence initially obtained can be compared to the sequence obtained from the new template.
  • Sequencing methods of the invention preferably comprise template/primer duplex attached to a surface. Individual nucleotides added to the surface comprise a detectable label—preferably an optically-detectable label, such as a fluorescent label. Each nucleotide species can comprise a different label, or can comprise the same label. In a preferred embodiment, each duplex is individually optically resolvable in order to facilitate single molecule sequence discrimination. The choice of a surface for attachment of duplex depends upon the detection method employed. Preferred surfaces for methods of the invention include epoxide surfaces and polyelectrolyte multilayer surfaces, such as those described in Braslavsky, et al., supra. Surfaces preferably are deposited on a substrate that is amenable to optical detection of the surface chemistry, such as glass or silica.
  • Nucleotides useful in the invention include any nucleotide or nucleotide analog, whether naturally-occurring or synthetic. For example, preferred nucleotides include phosphate esters of deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, adenosine, cytidine, guanosine, and uridine.
  • Polymerases useful in the invention include any nucleic acid polymerase capable of catalyzing a template-dependent addition of a nucleotide or nucleotide analog to a primer. Depending on the characteristics of the target nucleic acid, a DNA polymerase, an RNA polymerase, a reverse transcriptase, or a mutant or altered form of any of the foregoing can be used. According to one aspect of the invention, a thermophilic polymerase is used, such as ThermoSequenase®, 9°N™, Therminator™, Taq, Tne, Tma, Pfu, Tfl, Tth, Tli, Stoffel fragment, Vent™ and Deep Vent™ DNA polymerase.
  • BRIEF DESCRIPTION OF THE DRAWING
  • The FIGURE shows a schematic representation of one embodiment of the present invention.
  • DETAILED DESCRIPTION
  • The invention provides methods and compositions for improving the accuracy of nucleic acid sequencing-by-synthesis reactions by re-sequencing a least a portion of a template nucleic acid. While applicable to bulk sequencing methods, the invention is particularly useful in connection with single molecule sequencing methods. According to the invention, the methods comprise the steps of exposing a duplex comprising a template and a primer to a polymerase and one or more nucleotide comprising a detectable label under conditions sufficient for template-dependent nucleotide addition to the primer. In one embodiment, the template is individually optically resolvable. Any unincorporated labeled nucleotide is optionally washed way. Any nucleotide incorporated into the primer is identified by detecting the label associated with the incorporated nucleotide. The steps of exposing duplex to polymerase and another nucleotide comprising a detectable label and polymerizing, optional washing, and identification are repeated, thereby determining a nucleotide sequence. As a result of the exposing and polymerizing steps, the primer is extended by the addition of one or more nucleotides that are complementary to the corresponding positions of the template. The template is then removed from the duplex, leaving the extended primer. A polynucleotide is added to the 3′ terminus of the primer or extended primer, thereby forming a modified primer. The modified primer is used as the template in subsequent sequencing reactions.
  • The FIGURE is a schematic representation of one embodiment of the invention. In this embodiment, a primer, 2, is attached to a solid support, 3. A template, 1, is hybridized to the primer, forming a template/primer duplex. In step A, the template primer/duplex is exposed to a polymerase and at least one nucleotide comprising a detectable label, under conditions sufficient for template-dependent nucleotide addition to said primer. If the nucleotide is complementary to the template nucleotide immediately downstream of the primer, a nucleotide is added to the primer. After identifying nucleotide incorporated into the primer, the process is repeated, thereby adding a second nucleotide to the primer in a template dependent manner, and so on. As shown in the FIGURE, as a result of repeating the process, template complementary sequence, 4, is added to the primer. After the process has been repeated the desired number of times, the template is removed as shown in step B, leaving the extended primer. In step C, a polynucleotide, 6, is added to the extended primer at the 3′ terminus (e.g., downstream of the previously added template complementary sequence) forming a new template for sequencing in the opposite direction. In step D, a primer capable of hybridizing to the polynucleotide is added, forming a template/primer duplex, 7. The process of adding nucleotide and polymerase, detecting incorporated nucleotide and repeating the desired number of times is then repeated using the modified extended primer as a template, as shown in step E, thereby sequencing the template complementary sequence 4, 8. As a result, the primer, 6, is extended by the addition of sequence 8 that corresponds to at least a portion of the original template, 1. The extended primer (6, 8) can be removed, F, and the template can be resequenced, as described above.
  • In a preferred embodiment of the invention, direct amine attachment is used to attach primer or template to an epoxide surface. The primer or the template can comprise an optically-detectable label in order to determine the location of duplex on the surface. At least a portion of the duplex is optically resolvable from other duplexes on the surface. The surface is preferably passivated with a reagent that occupies portions of the surface that might, absent passivation, fluoresce. Optimal passivation reagents include amines, phosphate, water, sulfates, detergents, and other reagents that reduce native or accumulating surface fluorescence. Sequencing is then accomplished by presenting one or more labeled nucleotide in the presence of a polymerase under conditions that promote complementary base incorporation in the primer. In a preferred embodiment, one base at a time (per cycle) is added and all bases have the same label. There is a wash step after each incorporation cycle, and the label is either neutralized without removal or removed from incorporated nucleotides. After the completion of a predetermined number of cycles of base addition, the linear sequence data for each individual duplex is compiled. Numerous algorithms are available for sequence compilation and alignment as discussed below.
  • In general, epoxide-coated glass surfaces are used for direct amine attachment of templates, primers, or both. Amine attachment to the termini of template and primer molecules is accomplished using terminal transferase. Primer molecules can be custom-synthesized to hybridize to templates for duplex formation.
  • A full-cycle is conducted as many times as necessary to complete sequencing of a desired length of template, or resequencing of the desired length of the template complementary sequence. Once the desired number of cycles is complete, the result is a stack of images represented in a computer database. For each spot on the surface that contained an initial individual duplex, there will be a series of light and dark image coordinates, corresponding to whether a base was incorporated in any given cycle. For example, if the template sequence was TACGTACG and nucleotides were presented in the order CAGU(T), then the duplex would be “dark” (i.e., no detectable signal) for the first cycle (presentation of C), but would show signal in the second cycle (presentation of A, which is complementary to the first T in the template sequence). The same duplex would produce signal upon presentation of the G, as that nucleotide is complementary to the next available base in the template, C. Upon the next cycle (presentation of U), the duplex would be dark, as the next base in the template is G. Upon presentation of numerous cycles, the sequence of the template would be built up through the image stack. The sequencing data are then fed into an aligner as described below for resequencing, or are compiled for de novo sequencing as the linear order of nucleotides incorporated into the primer.
  • The imaging system used in practice of the invention can be any system that provides sufficient illumination of the sequencing surface at a magnification such that single fluorescent molecules can be resolved.
  • General Considerations
  • A. Nucleic Acid Templates
  • Nucleic acid templates include deoxyribonucleic acid (DNA) and/or ribonucleic acid (RNA). Nucleic acid template molecules can be isolated from a biological sample containing a variety of other components, such as proteins, lipids and non-template nucleic acids. Nucleic acid template molecules can be obtained from any cellular material, obtained from an animal, plant, bacterium, fungus, or any other cellular organism. Biological samples for use in the invention also include viral particles or samples prepared from viral material. Nucleic acid template molecules may be obtained directly from an organism or from a biological sample obtained from an organism, e.g., from blood, urine, cerebrospinal fluid, seminal fluid, saliva, sputum, stool and tissue. Any tissue or body fluid specimen may be used as a source for nucleic acid for use in the invention. Nucleic acid template molecules may also be isolated from cultured cells, such as a primary cell culture or a cell line. The cells or tissues from which template nucleic acids are obtained can be infected with a virus or other intracellular pathogen. A sample can also be total RNA extracted from a biological specimen, a cDNA library, viral, or genomic DNA.
  • Nucleic acid obtained from biological samples typically is fragmented to produce suitable fragments for analysis. In one embodiment, nucleic acid from a biological sample is fragmented by sonication. Nucleic acid template molecules can be obtained as described in U.S. Patent Application 2002/0190663 A1, published Oct. 9, 2003, the teachings of which are incorporated herein in their entirety. Generally, nucleic acid can be extracted from a biological sample by a variety of techniques such as those described by Maniatis, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y., pp. 280-281 (1982). Generally, individual nucleic acid template molecules can be from about 5 bases to about 20 kb. Nucleic acid molecules may be single-stranded, double-stranded, or double-stranded with single-stranded regions (for example, stem- and loop-structures).
  • A biological sample as described herein may be homogenized or fractionated in the presence of a detergent or surfactant. The concentration of the detergent in the buffer may be about 0.05% to about 10.0%. The concentration of the detergent can be up to an amount where the detergent remains soluble in the solution. In a preferred embodiment, the concentration of the detergent is between 0.1% to about 2%. The detergent, particularly a mild one that is nondenaturing, can act to solubilize the sample. Detergents may be ionic or nonionic. Examples of nonionic detergents include triton, such as the Triton® X series (Triton® X-100 t-Oct-C6H4—(OCH2—CH2)xOH, x=9-10, Triton® X-100R, Triton® X-114 x=7-8), octyl glucoside, polyoxyethylene(9)dodecyl ether, digitonin, IGEPAL® CA630 octylphenyl polyethylene glycol, n-octyl-beta-D-glucopyranoside (betaOG), n-dodecyl-beta, Tween® 20 polyethylene glycol sorbitan monolaurate, Tween® 80 polyethylene glycol sorbitan monooleate, polidocanol, n-dodecyl beta-D-maltoside (DDM), NP-40 nonylphenyl polyethylene glycol, C12E8 (octaethylene glycol n-dodecyl monoether), hexaethyleneglycol mono-n-tetradecyl ether (C14EO6), octyl-beta-thioglucopyranoside (octyl thioglucoside, OTG), Emulgen, and polyoxyethylene 10 lauryl ether (C12E10). Examples of ionic detergents (anionic or cationic) include deoxycholate, sodium dodecyl sulfate (SDS), N-lauroylsarcosine, and cetyltrimethylammoniumbromide (CTAB). A zwitterionic reagent may also be used in the purification schemes of the present invention, such as Chaps, zwitterion 3-14, and 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulf-onate. It is contemplated also that urea may be added with or without another detergent or surfactant.
  • Lysis or homogenization solutions may further contain other agents, such as reducing agents. Examples of such reducing agents include dithiothreitol (DTT), β-mercaptoethanol, DTE, GSH, cysteine, cysteamine, tricarboxyethyl phosphine (TCEP), or salts of sulfurous acid.
  • B. Nucleotides
  • Nucleotides useful in the invention include any nucleotide or nucleotide analog, whether naturally-occurring or synthetic. For example, preferred nucleotides include phosphate esters of deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, adeno sine, cytidine, guano sine, and uridine. Other nucleotides useful in the invention comprise an adenine, cytosine, guanine, thymine base, a xanthine or hypoxanthine; 5-bromouracil, 2-aminopurine, deoxyinosine, or methylated cytosine, such as 5-methylcytosine, and N4-methoxydeoxycytosine. Also included are bases of polynucleotide mimetics, such as methylated nucleic acids, e.g., 2′-O-methRNA, peptide nucleic acids, modified peptide nucleic acids, locked nucleic acids and any other structural moiety that can act substantially like a nucleotide or base, for example, by exhibiting base-complementarity with one or more bases that occur in DNA or RNA and/or being capable of base-complementary incorporation, and includes chain-terminating analogs. A nucleotide corresponds to a specific nucleotide species if they share base-complementarity with respect to at least one base.
  • Nucleotides for nucleic acid sequencing according to the invention preferably comprise a detectable label that is directly or indirectly detectable. Preferred labels include optically-detectable labels, such as fluorescent labels. Examples of fluorescent labels include, but are not limited to, 4-acetamido-4′-isothiocyanatostilbene-2,2′disulfonic acid; acridine and derivatives: acridine, acridine isothiocyanate; 5-(2′-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS); 4-amino-N-[3-vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate; N-(4-anilino-1-naphthyl)maleimide; anthranilamide; BODIPY; Brilliant Yellow; coumarin and derivatives; coumarin, 7-amino-4-methylcoumarin (AMC, Coumarin 120), 7-amino-4-trifluoromethylcouluarin (Coumaran 151); cyanine dyes; cyanosine; 4′,6-diaminidino-2-phenylindole (DAPI); 5′ 5 dibromopyrogallol-sulfonaphthalein (Bromopyrogallol Red); 7-diethylamino-3-(4′-isothiocyanatophenyl)-4-methylcoumarin; diethylenetriamine pentaacetate; 4,4′-diisothiocyanatodihydro-stilbene-2,2′-disulfonic acid; 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid; 5-[dimethylamino]naphthalene-1-sulfonyl chloride (DNS, dansylchloride); 4-dimethylaminophenylazophenyl-4′-isothiocyanate (DABITC); eosin and derivatives; eosin, eosin isothiocyanate, erythrosin and derivatives; erythrosin B, erythrosin, isothiocyanate; ethidium; fluorescein and derivatives; 5-carboxyfluorescein (FAM), 5-(4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF), 2′,7′-dimethoxy-4′5′-dichloro-6-carboxyfluorescein, fluorescein, fluorescein isothiocyanate, QFITC, (XRITC); fluorescamine; IR144; IR1446; Malachite Green isothiocyanate; 4-methylumbelliferoneortho cresolphthalein; nitrotyrosine; pararosaniline; Phenol Red; B-phycoerythrin; o-phthaldialdehyde; pyrene and derivatives: pyrene, pyrene butyrate, succinimidyl 1-pyrene; butyrate quantum dots; Reactive Red 4 (Cibacron™ Brilliant Red 3B-A) rhodamine and derivatives: 6-carboxy-X-rhodamine (ROX), 6-carboxyrhodamine (R6G), lissamine rhodamine B sulfonyl chloride rhodamine (Rhod), rhodamine B, rhodamine 123, rhodamine X isothiocyanate, sulforhodamine B, sulforhodamine 101, sulfonyl chloride derivative of sulforhodamine 101 (Texas Red); N,N,N′,N′tetramethyl-6-carboxyrhodamine (TAMRA); tetramethyl rhodamine; tetramethyl rhodamine isothiocyanate (TRITC); riboflavin; rosolic acid; terbium chelate derivatives; Cy3; Cy5; Cy5.5; Cy7; IRD 700; IRD 800; La Jolta Blue; phthalo cyanine; and naphthalo cyanine. Preferred fluorescent labels are cyanine-3 and cyanine-5. Labels other than fluorescent labels are contemplated by the invention, including other optically-detectable labels.
  • C. Nucleic Acid Polymerases
  • Nucleic acid polymerases generally useful in the invention include DNA polymerases, RNA polymerases, reverse transcriptases, and mutant or altered forms of any of the foregoing. DNA polymerases and their properties are described in detail in, among other places, DNA Replication 2nd edition, Komberg and Baker, W. H. Freeman, New York, N.Y. (1991). Known conventional DNA polymerases useful in the invention include, but are not limited to, Pyrococcus furiosus (Pfu) DNA polymerase (Lundberg et al., 1991, Gene, 108: 1, Stratagene), Pyrococcus woesei (Pwo) DNA polymerase (Hinnisdaels et al., 1996, Biotechniques, 20:186-8, Boehringer Mannheim), Thermus thermophilus (Tth) DNA polymerase (Myers and Gelfand 1991, Biochemistry 30:7661), Bacillus stearothermophilus DNA polymerase (Stenesh and McGowan, 1977, Biochim Biophys Acta 475:32), Thermococcus litoralis (Tli) DNA polymerase (also referred to as Vent™ DNA polymerase, Cariello et al., 1991, Polynucleotides Res, 19: 4193, New England Biolabs), 9°Nm™ DNA polymerase (New England Biolabs), Stoffel fragment, ThermoSequenase® (Amersham Pharmacia Biotech UK), Therminator™ (New England Biolabs), Thermotoga maritima (Tma) DNA polymerase (Diaz and Sabino, 1998 Braz J Med. Res, 31:1239), Thermus aquaticus (Taq) DNA polymerase (Chien et al., 1976, J. Bacteoriol, 127: 1550), DNA polymerase, Pyrococcus kodakaraensis KOD DNA polymerase (Takagi et al., 1997, Appl. Environ. Microbiol. 63:4504), JDF-3 DNA polymerase (from thermococcus sp. JDF-3, Patent application WO 0132887), Pyrococcus GB-D (PGB-D) DNA polymerase (also referred as Deep Vent™ DNA polymerase, Juncosa-Ginesta et al., 1994, Biotechniques, 16:820, New England Biolabs), UlTma DNA polymerase (from thermophile Thermotoga maritima; Diaz and Sabino, 1998 Braz J. Med. Res, 31:1239; PE Applied Biosystems), Tgo DNA polymerase (from thermococcus gorgonarius, Roche Molecular Biochemicals), E. coli DNA polymerase I (Lecomte and Doubleday, 1983, Polynucleotides Res. 11:7505), T7 DNA polymerase (Nordstrom et al., 1981, J Biol. Chem. 256:3112), and archaeal DP1I/DP2 DNA polymerase II (Cann et al., 1998, Proc Natl Acad. Sci. USA 95:14250-->5).
  • While mesophilic polymerases are contemplated by the invention, preferred polymerases are thermophilic. Thermophilic DNA polymerases include, but are not limited to, ThermoSequenase®, 9°N™, Therminator™, Taq, Tne, Tma, Pfu, Tfl, Tth, Tli, Stoffel fragment, Vent™ and Deep Vent™ DNA polymerase, KOD DNA polymerase, Tgo, JDF-3, and mutants, variants and derivatives thereof.
  • Reverse transcriptases useful in the invention include, but are not limited to, reverse transcriptases from HIV, HTLV-1, HTLV-II, FeLV, FIV, SIV, AMV, MMTV, MoMuLV and other retroviruses (see Levin, Cell 88:5-8 (1997); Verma, Biochim Biophys Acta. 473:1-38 (1977); Wu et al., CRC Crit Rev Biochem. 3:289-347 (1975)).
  • D. Surfaces
  • In a preferred embodiment, nucleic acid template molecules are attached to a substrate (also referred to herein as a surface) and subjected to analysis by sequencing as taught herein. Nucleic acid template molecules are attached to the surface such that the template/primer duplexes are individually optically resolvable. Substrates for use in the invention can be two- or three-dimensional and can comprise a planar surface (e.g., a glass slide) or can be shaped. A substrate can include glass (e.g., controlled pore glass (CPG)), quartz, plastic (such as polystyrene (low cross-linked and high cross-linked polystyrene), polycarbonate, polypropylene and poly(methymethacrylate)), acrylic copolymer, polyamide, silicon, metal (e.g., alkanethiolate-derivatized gold), cellulose, nylon, latex, dextran, gel matrix (e.g., silica gel), polyacrolein, or composites.
  • Suitable three-dimensional substrates include, for example, spheres, microparticles, beads, membranes, slides, plates, micromachined chips, tubes (e.g., capillary tubes), microwells, microfluidic devices, channels, filters, or any other structure suitable for anchoring a nucleic acid. Substrates can include planar arrays or matrices capable of having regions that include populations of template nucleic acids or primers. Examples include nucleoside-derivatized CPG and polystyrene slides; derivatized magnetic slides; polystyrene grafted with polyethylene glycol, and the like.
  • In one embodiment, a substrate is coated to allow optimum optical processing and nucleic acid attachment. Substrates for use in the invention can also be treated to reduce background. Exemplary coatings include epoxides, and derivatized epoxides (e.g., with a binding molecule, such as streptavidin). The surface can also be treated to improve the positioning of attached nucleic acids (e.g., nucleic acid template molecules, primers, or template molecule/primer duplexes) for analysis. As such, a surface according to the invention can be treated with one or more charge layers (e.g., a negative charge) to repel a charged molecule (e.g., a negatively charged labeled nucleotide). For example, a substrate according to the invention can be treated with polyallylamine followed by polyacrylic acid to form a polyelectrolyte multilayer. The carboxyl groups of the polyacrylic acid layer are negatively charged and thus repel negatively charged labeled nucleotides, improving the positioning of the label for detection. Coatings or films applied to the substrate should be able to withstand subsequent treatment steps (e.g., photoexposure, boiling, baking, soaking in warm detergent-containing liquids, and the like) without substantial degradation or disassociation from the substrate.
  • Examples of substrate coatings include, vapor phase coatings of 3-aminopropyltrimethoxysilane, as applied to glass slide products, for example, from Molecular Dynamics, Sunnyvale, Calif. In addition, generally, hydrophobic substrate coatings and films aid in the uniform distribution of hydrophilic molecules on the substrate surfaces. Importantly, in those embodiments of the invention that employ substrate coatings or films, the coatings or films that are substantially non-interfering with primer extension and detection steps are preferred. Additionally, it is preferable that any coatings or films applied to the substrates either increase template molecule binding to the substrate or, at least, do not substantially impair template binding.
  • Various methods can be used to anchor or immobilize the primer to the surface of the substrate. The immobilization can be achieved through direct or indirect bonding to the surface. The bonding can be by covalent linkage. See, Joos et al., Analytical Biochemistry 247:96-101, 1997; Oroskar et al., Clin. Chem. 42:1547-1555, 1996; and Khandjian, Mol. Bio. Rep. 11:107-115, 1986. A preferred attachment is direct amine bonding of a terminal nucleotide of the template or the primer to an epoxide integrated on the surface. The bonding also can be through non-covalent linkage. For example, biotin-streptavidin (Taylor et al., J. Phys. D. Appl. Phys. 24:1443, 1991) and digoxigenin with anti-digoxigenin (Smith et al., Science 253:1122, 1992) are common tools for anchoring nucleic acids to surfaces and parallels. Alternatively, the attachment can be achieved by anchoring a hydrophobic chain into a lipid monolayer or bilayer. Other methods for known in the art for attaching nucleic acid molecules to substrates also can be used.
  • E. Detection
  • Any detection method may be used that is suitable for the type of label employed. Thus, exemplary detection methods include radioactive detection, optical absorbance detection, e.g., UV-visible absorbance detection, optical emission detection, e.g., fluorescence or chemiluminescence. For example, extended primers can be detected on a substrate by scanning all or portions of each substrate simultaneously or serially, depending on the scanning method used. For fluorescence labeling, selected regions on a substrate may be serially scanned one-by-one or row-by-row using a fluorescence microscope apparatus, such as described in Fodor (U.S. Pat. No. 5,445,934) and Mathies et al. (U.S. Pat. No. 5,091,652). Devices capable of sensing fluorescence from a single molecule include scanning tunneling microscope (siM) and the atomic force microscope (AFM). Hybridization patterns may also be scanned using a CCD camera (e.g., Model TE/CCD512SF, Princeton Instruments, Trenton, N.J.) with suitable optics (Ploem, in Fluorescent and Luminescent Probes for Biological Activity Mason, T. G. Ed., Academic Press, Landon, pp. 1-11 (1993), such as described in Yershov et al., Proc. Natl. Aca. Sci. 93:4913 (1996), or may be imaged by TV monitoring. For radioactive signals, a phosphorimager device can be used (Johnston et al., Electrophoresis, 13:566, 1990; Drmanac et al., Electrophoresis, 13:566, 1992; 1993). Other commercial suppliers of imaging instruments include General Scanning Inc., (Watertown, Mass. on the World Wide Web at genscan.com), Genix Technologies (Waterloo, Ontario, Canada; on the World Wide Web at confocal.com), and Applied Precision Inc. Such detection methods are particularly useful to achieve simultaneous scanning of multiple attached template nucleic acids.
  • A number of approaches can be used to detect incorporation of fluorescently-labeled nucleotides into a single nucleic acid molecule. Optical setups include near-field scanning microscopy, far-field confocal microscopy, wide-field epi-illumination, light scattering, dark field microscopy, photoconversion, single and/or multiphoton excitation, spectral wavelength discrimination, fluorophore identification, evanescent wave illumination, and total internal reflection fluorescence (TIRF) microscopy. In general, certain methods involve detection of laser-activated fluorescence using a microscope equipped with a camera. Suitable photon detection systems include, but are not limited to, photodiodes and intensified CCD cameras. For example, an intensified charge couple device (ICCD) camera can be used. The use of an ICCD camera to image individual fluorescent dye molecules in a fluid near a surface provides numerous advantages. For example, with an ICCD optical setup, it is possible to acquire a sequence of images (movies) of fluorophores.
  • Some embodiments of the present invention use TIRF microscopy for two-dimensional imaging. TIRF microscopy uses totally internally reflected excitation light and is well known in the art. See, e.g., the World Wide Web at nikon-instrumentsjp/eng/page/products/tirf.aspx. In certain embodiments, detection is carried out using evanescent wave illumination and total internal reflection fluorescence microscopy. An evanescent light field can be set up at the surface, for example, to image fluorescently-labeled nucleic acid molecules. When a laser beam is totally reflected at the interface between a liquid and a solid substrate (e.g., a glass), the excitation light beam penetrates only a short distance into the liquid. The optical field does not end abruptly at the reflective interface, but its intensity falls off exponentially with distance. This surface electromagnetic field, called the “evanescent wave”, can selectively excite fluorescent molecules in the liquid near the interface. The thin evanescent optical field at the interface provides low background and facilitates the detection of single molecules with high signal-to-noise ratio at visible wavelengths.
  • The evanescent field also can image fluorescently-labeled nucleotides upon their incorporation into the attached template/primer complex in the presence of a polymerase. Total internal reflectance fluorescence microscopy is then used to visualize the attached template/primer duplex and/or the incorporated nucleotides with single molecule resolution.
  • F. Analysis
  • Alignment and/or compilation of sequence results obtained from the image stacks produced as generally described above utilizes look-up tables that take into account possible sequences changes (due, e.g., to errors, mutations, etc.). Essentially, sequencing results obtained as described herein are compared to a look-up type table that contains all possible reference sequences plus 1 or 2 base errors.
  • In resequencing, a preferred embodiment for sequence alignment compares sequences obtained to a database of reference sequences of the same length, or within 1 or 2 bases of the same length, from the initially obtained sequence or the target sequence contained in a look-up table format. In a preferred embodiment, the look-up table contains exact matches with respect to the reference sequence and sequences of the prescribed length or lengths that have one or two errors (e.g., 9-mers with all possible 1-base or 2-base errors). The obtained sequences are then matched to the sequences on the look-up table and given a score that reflects the uniqueness of the match to sequence(s) in the table. The obtained sequences are then aligned to the reference sequence based upon the position at which the obtained sequence best matches a portion of the reference sequence. More detail on the alignment process is provided below in the Example.
  • EXAMPLE
  • The 7249 nucleotide genome of the bacteriophage M13mp18 was sequenced using single molecule methods of the invention. Purified, single-stranded viral M13mp18 genomic DNA was obtained from New England Biolabs. Approximately 25 ug of M13 DNA was digested to an average fragment size of 40 bp with 0.1 U Dnase I (New England Biolabs) for 10 minutes at 37° C. Digested DNA fragment sizes were estimated by running an aliquot of the digestion mixture on a precast denaturing (TBE-Urea) 10% polyacrylamide gel (Novagen) and staining with SYBR Gold (Invitrogen/Molecular Probes). The DNase I-digested genomic DNA was filtered through a YM10 ultrafiltration spin column (Millipore) to remove small digestion products less than about 30 nt. Approximately 20 pmol of the filtered DNase I digest was then polyadenylated with terminal transferase according to known methods (Roychoudhury, R and Wu, R. 1980, Terminal transferase-catalyzed addition of nucleotides to the 3′ termini of DNA. Methods Enzymol. 65(1):43-62.). The average dA tail length was 50+/−5 nucleotides. Terminal transferase was then used to label the fragments with Cy3-dUTP. Fragments were then terminated with dideoxyTTP (also added using terminal transferase). The resulting fragments were again filtered with a YM10 ultrafiltration spin column to remove free nucleotides and stored in ddH2O at −20° C.
  • Epoxide-coated glass slides were prepared for oligo attachment. Epoxide-functionalized 40 mm diameter #1.5 glass cover slips (slides) were obtained from Erie Scientific (Salem, N.H.). The slides were preconditioned by soaking in 3×SSC for 15 minutes at 37° C. Next, a 500 pM aliquot of 5′ aminated polydT(50) primer (polythymidine of 50 nucleotides in length with a 5′ terminal amine) is incubated with each slide for 30 minutes at room temperature in a volume of 80 ml. The resulting slides have primer attached by direct amine linkage to the epoxide. The slides are then treated with phosphate (1 M) for 4 hours at room temperature in order to passivate the surface. Slides re then stored in polymerase rinse buffer (20 mM Tris, 100 mM NaCl, 0.001% Triton X-100, pH 8.0) until they are used for sequencing.
  • For sequencing, the slides are placed in a modified FCS2 flow cell (Bioptechs, Butler, Pa.) using a 50 um thick gasket The flow cell is placed on a movable stage that is part of a high-efficiency fluorescence imaging system built around a Nikon TE-2000 inverted microscope equipped with a total internal reflection (TIR) objective. The slide is then rinsed with HEPES buffer with 100 mM NaCl and equilibrated to a temperature of 50° C. An aliquot of poly(dT50) template is placed in the flow cell and incubated on the slide for 15 minutes. After incubation, the flow cell is rinsed with 1×SSC/HEPES/0.1% SDS followed by HEPES/NaCl. A passive vacuum apparatus is used to pull fluid across the flow cell. The resulting slide contains M13 template/primer duplex. The temperature of the flow cell is then reduced to 37° C. for sequencing and the objective is brought into contact with the flow cell.
  • For sequencing, cytosine triphosphate, guanidine triphosphate, adenine triphosphate, and uracil triphosphate, each having a cyanine-5 label (at the 7-deaza position for ATP and GTP and at the C5 position for CTP and UTP (PerkinElmer)) are stored separately in buffer containing 20 mM Tris-HCl, pH 8.8, 10 mM MgSO4, 10 mM (NH4)2SO4, 10 mM HCl, and 0.1% Triton X-100, and 100 U Klenow exo polymerase (NEN). Sequencing proceeds as follows.
  • First, initial imaging is used to determine the positions of duplex on the epoxide surface. The Cy3 label attached to the M13 templates is imaged by excitation using a laser tuned to 532 nm radiation (Verdi V-2 Laser, Coherent, Inc., Santa Clara, Calif.) in order to establish duplex position. For each slide only single fluorescent molecules imaged in this step are counted. Imaging of incorporated nucleotides as described below is accomplished by excitation of a cyanine-5 dye using a 635 nm radiation laser (Coherent). 5 uM Cy5CTP is placed into the flow cell and exposed to the slide for 2 minutes. After incubation, the slide is rinsed in 1×SSC/15 mM HEPES/0.1% SDS/pH 7.0 (“SSC/HEPES/SDS”) (15 times in 60 ul volumes each, followed by 150 mM HEPES/150 mM NaCl/pH 7.0 (“HEPES/NaCl”) (10 times at 60 ul volumes). An oxygen scavenger containing 30% acetonitrile and scavenger buffer (134 ul HEPES/NaCl, 24 ul 100 mM Trolox in MES, pH6.1, 10 ul DABCO in MES, pH6.1, 8 ul 2M glucose, 20 ul NaI (50 mM stock in water), and 4 ul glucose oxidase) is next added. The slide is then imaged (500 frames) for 0.2 seconds using an Inova301K laser (Coherent) at 647 nm, followed by green imaging with a Verdi V-2 laser (Coherent) at 532 nm for 2 seconds to confirm duplex position. The positions having detectable fluorescence are recorded. After imaging, the flow cell is rinsed 5 times each with SSC/HEPES/SDS (60 ul) and HEPES/NaCl (60 ul). Next, the cyanine-5 label is cleaved off incorporated CTP by introduction into the flow cell of 50 mM TCEP for 5 minutes, after which the flow cell is rinsed 5 times each with SSC/HEPES/SDS (60 ul) and HEPES/NaCl (60 ul). The remaining nucleotide is capped with 50 mM iodoacetamide for 5 minutes followed by rinsing 5 times each with SSC/HEPES/SDS (60 ul) and HEPES/NaCl (60 ul). The scavenger is applied again in the manner described above, and the slide is again imaged to determine the effectiveness of the cleave/cap steps and to identify non-incorporated fluorescent objects.
  • The procedure described above is then conducted 100 nM Cy5dATP, followed by 100 nM Cy5dGTP, and finally 500 nM Cy5dUTP. The procedure (expose to nucleotide, polymerase, rinse, scavenger, image, rinse, cleave, rinse, cap, rinse, scavenger, final image) is repeated exactly as described for ATP, GTP, and UTP except that Cy5dUTP is incubated for 5 minutes instead of 2 minutes. Uridine is used instead of Thymidine due to the fact that the Cy5 label is incorporated at the position normally occupied by the methyl group in Thymidine triphosphate, thus turning the dTTP into dUTP. In all 64 cycles (C, A, G, U) are conducted as described in this and the preceding paragraph.
  • Once the desired number of cycles are completed, the image stack data (i.e., the single molecule sequences obtained from the various surface-bound duplex) are aligned to the M13 reference sequence. The image data obtained can be compressed to collapse homopolymeric regions. Thus, the sequence “TCAAAGC” is represented as “TCAGC” in the data tags used for alignment. Similarly, homopolymeric regions in the reference sequence are collapsed for alignment.
  • The alignment algorithm matches sequences obtained as described above with the actual M13 linear sequence. Placement of obtained sequence on M13 is based upon the best match between the obtained sequence and a portion of M13 of the same length, taking into consideration 0, 1, or 2 possible errors. All obtained 9-mers with 0 errors (meaning that they exactly match a 9-mer in the M13 reference sequence) are first aligned with M13. Then 10-, 11-, and 12-mers with 0 or 1 error are aligned. Finally, all 13-mers or greater with 0, 1, or 2 errors are aligned.
  • The template fragments are removed by increasing the temperature of the flow cell above the melting temperature of the duplex, thereby releasing the template fragments from the duplexes. The free templates are removed from the flow cell by washing the flow cell, for example the flow cell can be rinsed 5 times each with SSC/HEPES/SDS (60 ul) and HEPES/NaCl (60 ul).
  • The primers are then modified by adding a polynucleotide sequence to the 3′ terminus of the primer. The oligonucleotide-modified primers are then used as the template in subsequent polymerization reactions. Free primer capable of hybridizing to the added oligonucleotide is added to the flow cell and incubated under conditions sufficient to allow hybridization between the added oligonucleotide portion of the template and the free primer. After incubation, the flow cell is rinsed with 1×SSC/HEPES/0.1% SDS followed by HEPES/NaCl. The resulting slide contains template/primer duplexes where the template comprises the original primer having M13 template complementary sequences added thereto and modified with an oligonucleotide. The temperature of the flow cell is then reduced to 37° C. for sequencing and the objective is brought into contact with the flow cell. The procedure (expose to nucleotide, polymerase, rinse, scavenger, image, rinse, cleave, rinse, cap, rinse, scavenger, final image) is repeated as described above.
  • Once the desired number of cycles is completed, the image stack data (i.e., the single molecule sequences obtained from the various surface-bound duplex) are aligned to the M13 reference sequence and/or are aligned to the sequence initially obtained as described above. The image data obtained can be compressed to collapse homopolymeric regions as described above.
  • The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

Claims (8)

1. A method of increasing accuracy of nucleic acid sequencing, the method comprising the steps of:
a) exposing a duplex comprising a template and a primer to a polymerase and one or more nucleotide comprising a detectable label under conditions sufficient for template-dependent nucleotide addition to said primer, wherein said template is individually optically resolvable;
b) identifying nucleotide incorporated into said primer;
c) repeating steps a) and b), thereby determining a nucleotide sequence;
d) removing the template from the primer of step c);
e) adding a polynucleotide to a 3′ terminus of the primer of step d) to form a template;
f) exposing the template of step e) to a primer capable of hybridizing to said added polynucleotide to form template/primer duplex, and repeating steps a) through c) to sequence a portion of the template, wherein a least a portion of the sequence obtained is complementary to the nucleotide sequence of c), thereby increasing the accuracy of nucleic acid sequencing.
2. The method of claim 1, wherein the sequence obtained in c) is compared with a complement of the sequence obtained in f).
3. The method of claim 1, further comprising repeating steps d) and f).
4. The method of claim 1, wherein said label is an optically-detectable label.
5. The method of claim 4, wherein said optically-detectable label is a fluorescent label.
6. The method of claim 5, wherein said fluorescent label is selected from the group consisting of fluorescein, rhodamine, cyanine, Cy5, Cy3, BODIPY, alexa, and derivatives thereof.
7. The method of claim 1, wherein said duplex is attached to a surface.
8. The method of claim 1, wherein said primer is attached to a surface.
US11/872,436 2006-04-14 2007-10-15 Methods for increasing accuracy of nucleic acid sequencing Abandoned US20090053705A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/872,436 US20090053705A1 (en) 2006-04-14 2007-10-15 Methods for increasing accuracy of nucleic acid sequencing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/404,695 US7282337B1 (en) 2006-04-14 2006-04-14 Methods for increasing accuracy of nucleic acid sequencing
US11/872,436 US20090053705A1 (en) 2006-04-14 2007-10-15 Methods for increasing accuracy of nucleic acid sequencing

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/404,695 Continuation US7282337B1 (en) 2006-04-14 2006-04-14 Methods for increasing accuracy of nucleic acid sequencing

Publications (1)

Publication Number Publication Date
US20090053705A1 true US20090053705A1 (en) 2009-02-26

Family

ID=38997463

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/404,695 Expired - Fee Related US7282337B1 (en) 2006-04-14 2006-04-14 Methods for increasing accuracy of nucleic acid sequencing
US11/872,436 Abandoned US20090053705A1 (en) 2006-04-14 2007-10-15 Methods for increasing accuracy of nucleic acid sequencing

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/404,695 Expired - Fee Related US7282337B1 (en) 2006-04-14 2006-04-14 Methods for increasing accuracy of nucleic acid sequencing

Country Status (7)

Country Link
US (2) US7282337B1 (en)
EP (1) EP2007908B1 (en)
JP (1) JP2009533060A (en)
AT (1) ATE474938T1 (en)
CA (1) CA2649291A1 (en)
DE (1) DE602007007924D1 (en)
WO (1) WO2008016399A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119455A1 (en) * 1997-02-12 2002-08-29 Chan Eugene Y. Methods and products for analyzing polymers
US20070172860A1 (en) * 2000-12-01 2007-07-26 Hardin Susan H Enzymatic nucleic acid synthesis: compositions and methods
US20100235105A1 (en) * 2001-07-09 2010-09-16 Life Technologies Corporation Method for analyzing dynamic detectable events at the single molecule level

Families Citing this family (288)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050916A1 (en) * 2002-12-02 2004-06-17 Solexa Limited Recovery of original template
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US7169560B2 (en) 2003-11-12 2007-01-30 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
EP1716254B1 (en) * 2004-02-19 2010-04-07 Helicos Biosciences Corporation Methods for analyzing polynucleotide sequences
US20100216153A1 (en) 2004-02-27 2010-08-26 Helicos Biosciences Corporation Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7311794B2 (en) 2004-05-28 2007-12-25 Wafergen, Inc. Methods of sealing micro wells
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
WO2007081387A1 (en) 2006-01-11 2007-07-19 Raindance Technologies, Inc. Microfluidic devices, methods of use, and kits for performing diagnostics
US7282337B1 (en) * 2006-04-14 2007-10-16 Helicos Biosciences Corporation Methods for increasing accuracy of nucleic acid sequencing
US20090075252A1 (en) * 2006-04-14 2009-03-19 Helicos Biosciences Corporation Methods for increasing accuracy of nucleic acid sequencing
US20080003142A1 (en) 2006-05-11 2008-01-03 Link Darren R Microfluidic devices
US9074242B2 (en) 2010-02-12 2015-07-07 Raindance Technologies, Inc. Digital analyte analysis
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
US9012390B2 (en) 2006-08-07 2015-04-21 Raindance Technologies, Inc. Fluorocarbon emulsion stabilizing surfactants
US11940413B2 (en) 2007-02-05 2024-03-26 IsoPlexis Corporation Methods and devices for sequencing nucleic acids in smaller batches
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2008151023A2 (en) 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US20100267041A1 (en) * 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
US8617811B2 (en) 2008-01-28 2013-12-31 Complete Genomics, Inc. Methods and compositions for efficient base calling in sequencing reactions
US20090156412A1 (en) * 2007-12-17 2009-06-18 Helicos Biosciences Corporation Surface-capture of target nucleic acids
US20090163366A1 (en) * 2007-12-24 2009-06-25 Helicos Biosciences Corporation Two-primer sequencing for high-throughput expression analysis
WO2009091798A1 (en) * 2008-01-16 2009-07-23 Helicos Biosciences Corporation Quantitative genetic analysis
US7767400B2 (en) * 2008-02-03 2010-08-03 Helicos Biosciences Corporation Paired-end reads in sequencing by synthesis
US8628940B2 (en) 2008-09-24 2014-01-14 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
US8236499B2 (en) * 2008-03-28 2012-08-07 Pacific Biosciences Of California, Inc. Methods and compositions for nucleic acid sample preparation
EP4230747A3 (en) 2008-03-28 2023-11-15 Pacific Biosciences Of California, Inc. Compositions and methods for nucleic acid sequencing
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
US8383369B2 (en) * 2008-09-24 2013-02-26 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
WO2010036287A1 (en) * 2008-09-24 2010-04-01 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
US8486630B2 (en) 2008-11-07 2013-07-16 Industrial Technology Research Institute Methods for accurate sequence data and modified base position determination
US9778188B2 (en) 2009-03-11 2017-10-03 Industrial Technology Research Institute Apparatus and method for detection and discrimination molecular object
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
CA2760439A1 (en) 2009-04-30 2010-11-04 Good Start Genetics, Inc. Methods and compositions for evaluating genetic markers
US9309566B2 (en) 2010-12-17 2016-04-12 Life Technologies Corporation Methods, compositions, systems, apparatuses and kits for nucleic acid amplification
US20120156728A1 (en) 2010-12-17 2012-06-21 Life Technologies Corporation Clonal amplification of nucleic acid on solid surface with template walking
US9309557B2 (en) 2010-12-17 2016-04-12 Life Technologies Corporation Nucleic acid amplification
US9334531B2 (en) 2010-12-17 2016-05-10 Life Technologies Corporation Nucleic acid amplification
DK2456892T3 (en) 2009-07-24 2014-12-08 Illumina Inc Procedure for sequencing of a polynukleotidskabelon
WO2011014811A1 (en) 2009-07-31 2011-02-03 Ibis Biosciences, Inc. Capture primers and capture sequence linked solid supports for molecular diagnostic tests
WO2011019993A2 (en) 2009-08-14 2011-02-17 Epicentre Technologies Corporation METHODS, COMPOSITIONS, AND KITS FOR GENERATING rRNA-DEPLETED SAMPLES OR ISOLATING rRNA FROM SAMPLES
JP2013503646A (en) 2009-09-08 2013-02-04 ラボラトリー コーポレイション オブ アメリカ ホールディングス Compositions and methods for diagnosing autism spectrum disorders
AU2010351560C1 (en) 2009-09-23 2015-10-08 Celmatix Inc. Methods and devices for assessing infertility and/or egg quality
WO2011042564A1 (en) 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
ES2628739T3 (en) 2009-10-15 2017-08-03 Ibis Biosciences, Inc. Multiple displacement amplification
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
CA2790434A1 (en) 2010-02-18 2011-08-25 Anthony P. Shuber Compositions and methods for treating cancer
US9482615B2 (en) 2010-03-15 2016-11-01 Industrial Technology Research Institute Single-molecule detection system and methods
US20110262989A1 (en) 2010-04-21 2011-10-27 Nanomr, Inc. Isolating a target analyte from a body fluid
US9476812B2 (en) 2010-04-21 2016-10-25 Dna Electronics, Inc. Methods for isolating a target analyte from a heterogeneous sample
US8841104B2 (en) 2010-04-21 2014-09-23 Nanomr, Inc. Methods for isolating a target analyte from a heterogeneous sample
JP2013527769A (en) 2010-05-06 2013-07-04 アイビス バイオサイエンシズ インコーポレイティッド Integrated sample preparation system and stabilized enzyme mixture
US9670243B2 (en) 2010-06-02 2017-06-06 Industrial Technology Research Institute Compositions and methods for sequencing nucleic acids
US8865078B2 (en) 2010-06-11 2014-10-21 Industrial Technology Research Institute Apparatus for single-molecule detection
US8865077B2 (en) 2010-06-11 2014-10-21 Industrial Technology Research Institute Apparatus for single-molecule detection
SG186787A1 (en) 2010-07-23 2013-02-28 Esoterix Genetic Lab Llc Identification of differentially represented fetal or maternal genomic regions and uses thereof
CA2811294C (en) 2010-09-16 2016-06-28 Ibis Biosciences, Inc. Stabilization of ozone-labile fluorescent dyes by thiourea
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
US9163281B2 (en) 2010-12-23 2015-10-20 Good Start Genetics, Inc. Methods for maintaining the integrity and identification of a nucleic acid template in a multiplex sequencing reaction
EP2658988B1 (en) 2010-12-27 2018-01-24 Ibis Biosciences, Inc. Nucleic acid sample preparation methods and compositions
EP3859011A1 (en) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Methods for forming mixed droplets
WO2012112804A1 (en) 2011-02-18 2012-08-23 Raindance Technoligies, Inc. Compositions and methods for molecular labeling
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
WO2012167142A2 (en) 2011-06-02 2012-12-06 Raindance Technolgies, Inc. Enzyme quantification
WO2012177792A2 (en) 2011-06-24 2012-12-27 Sequenom, Inc. Methods and processes for non-invasive assessment of a genetic variation
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013022778A1 (en) 2011-08-05 2013-02-14 Ibis Biosciences, Inc. Nucleic acid sequencing by electrochemical detection
US20130109583A1 (en) 2011-10-03 2013-05-02 Piraye Yurttas Beim Methods and devices for assessing risk to a putative offspring of developing a condition
US10196681B2 (en) 2011-10-06 2019-02-05 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9984198B2 (en) 2011-10-06 2018-05-29 Sequenom, Inc. Reducing sequence read count error in assessment of complex genetic variations
US20140242588A1 (en) 2011-10-06 2014-08-28 Sequenom, Inc Methods and processes for non-invasive assessment of genetic variations
US10424394B2 (en) 2011-10-06 2019-09-24 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9367663B2 (en) 2011-10-06 2016-06-14 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
CA2852665A1 (en) 2011-10-17 2013-04-25 Good Start Genetics, Inc. Analysis methods
WO2013063308A1 (en) 2011-10-25 2013-05-02 University Of Massachusetts An enzymatic method to enrich for capped rna, kits for performing same, and compositions derived therefrom
WO2013096838A2 (en) 2011-12-22 2013-06-27 Ibis Biosciences, Inc. Systems and methods for isolating nucleic acids
WO2013096819A2 (en) 2011-12-22 2013-06-27 Ibis Biosciences, Inc. Macromolecule positioning by electrical potential
WO2013096798A2 (en) 2011-12-22 2013-06-27 Ibis Biosciences, Inc. Amplification of a sequence from a ribonucleic acid
WO2013096799A1 (en) 2011-12-22 2013-06-27 Ibis Biosciences, Inc. Systems and methods for isolating nucleic acids from cellular samples
EP2794927B1 (en) 2011-12-22 2017-04-12 Ibis Biosciences, Inc. Amplification primers and methods
US9506113B2 (en) 2011-12-28 2016-11-29 Ibis Biosciences, Inc. Nucleic acid ligation systems and methods
US9803231B2 (en) 2011-12-29 2017-10-31 Ibis Biosciences, Inc. Macromolecule delivery to nanowells
WO2013104990A1 (en) 2012-01-09 2013-07-18 Oslo Universitetssykehus Hf Methods and biomarkers for analysis of colorectal cancer
CN108611398A (en) 2012-01-13 2018-10-02 Data生物有限公司 Genotyping is carried out by new-generation sequencing
HUE059847T2 (en) 2012-01-20 2023-01-28 Sequenom Inc Diagnostic processes that factor experimental conditions
EP3495817A1 (en) 2012-02-10 2019-06-12 Raindance Technologies, Inc. Molecular diagnostic screening assay
RS61631B1 (en) 2012-02-17 2021-04-29 Hutchinson Fred Cancer Res Compositions and methods for accurately identifying mutations
WO2013126741A1 (en) 2012-02-24 2013-08-29 Raindance Technologies, Inc. Labeling and sample preparation for sequencing
US9732387B2 (en) 2012-04-03 2017-08-15 The Regents Of The University Of Michigan Biomarker associated with irritable bowel syndrome and Crohn's disease
US8209130B1 (en) 2012-04-04 2012-06-26 Good Start Genetics, Inc. Sequence assembly
US8812422B2 (en) 2012-04-09 2014-08-19 Good Start Genetics, Inc. Variant database
US10227635B2 (en) 2012-04-16 2019-03-12 Molecular Loop Biosolutions, Llc Capture reactions
EP2844768B1 (en) 2012-04-30 2019-03-13 Raindance Technologies, Inc. Digital analyte analysis
ES2683707T3 (en) 2012-05-02 2018-09-27 Ibis Biosciences, Inc. DNA sequencing
WO2013166302A1 (en) 2012-05-02 2013-11-07 Ibis Biosciences, Inc. Nucleic acid sequencing systems and methods
EP2844773B1 (en) 2012-05-04 2017-08-16 Boreal Genomics Corp. Biomarker analysis using scodaphoresis
EP2847353B1 (en) 2012-05-10 2022-01-19 The General Hospital Corporation Methods for determining a nucleotide sequence
US10504613B2 (en) 2012-12-20 2019-12-10 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US10497461B2 (en) 2012-06-22 2019-12-03 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2014005076A2 (en) 2012-06-29 2014-01-03 The Regents Of The University Of Michigan Methods and biomarkers for detection of kidney disorders
EP2888371B1 (en) * 2012-08-24 2017-08-02 Life Technologies Corporation Methods, compositions, systems, apparatuses and kits for nucleic acid paired end sequencing
US10482994B2 (en) 2012-10-04 2019-11-19 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
ES2701750T3 (en) 2012-10-16 2019-02-25 Abbott Molecular Inc Procedures for sequencing a nucleic acid
US10162800B2 (en) 2012-10-17 2018-12-25 Celmatix Inc. Systems and methods for determining the probability of a pregnancy at a selected point in time
US9177098B2 (en) 2012-10-17 2015-11-03 Celmatix Inc. Systems and methods for determining the probability of a pregnancy at a selected point in time
US9836577B2 (en) 2012-12-14 2017-12-05 Celmatix, Inc. Methods and devices for assessing risk of female infertility
US9551704B2 (en) 2012-12-19 2017-01-24 Dna Electronics, Inc. Target detection
US9434940B2 (en) 2012-12-19 2016-09-06 Dna Electronics, Inc. Methods for universal target capture
US9995742B2 (en) 2012-12-19 2018-06-12 Dnae Group Holdings Limited Sample entry
US9599610B2 (en) 2012-12-19 2017-03-21 Dnae Group Holdings Limited Target capture system
US10000557B2 (en) 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
US9804069B2 (en) 2012-12-19 2017-10-31 Dnae Group Holdings Limited Methods for degrading nucleic acid
EP2946345B1 (en) 2013-01-17 2024-04-03 Personalis, Inc. Methods and systems for genetic analysis
US20130309666A1 (en) 2013-01-25 2013-11-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2014134403A2 (en) 2013-03-01 2014-09-04 Vivonics, Inc. Aptamers that bind cd271
WO2014152421A1 (en) 2013-03-14 2014-09-25 Good Start Genetics, Inc. Methods for analyzing nucleic acids
CN105378107A (en) 2013-03-14 2016-03-02 雅培分子公司 Multiplex methylation-specific amplification systems and methods
US9146248B2 (en) 2013-03-14 2015-09-29 Intelligent Bio-Systems, Inc. Apparatus and methods for purging flow cells in nucleic acid sequencing instruments
WO2014152937A1 (en) 2013-03-14 2014-09-25 Ibis Biosciences, Inc. Nucleic acid control panels
US9591268B2 (en) 2013-03-15 2017-03-07 Qiagen Waltham, Inc. Flow cell alignment methods and systems
EP2971140B1 (en) 2013-03-15 2019-01-16 Ibis Biosciences, Inc. Methods to assess contamination in dna sequencing
US9890425B2 (en) 2013-03-15 2018-02-13 Abbott Molecular Inc. Systems and methods for detection of genomic copy number changes
US10930368B2 (en) 2013-04-03 2021-02-23 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP2986762B1 (en) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9725724B2 (en) 2013-05-16 2017-08-08 Vivonics, Inc. Neutral nucleic acid ligands
IL300163B1 (en) 2013-05-24 2024-02-01 Sequenom Inc Methods and processes for non-invasive assessment of genetic variations
WO2014197377A2 (en) 2013-06-03 2014-12-11 Good Start Genetics, Inc. Methods and systems for storing sequence read data
KR102299305B1 (en) 2013-06-21 2021-09-06 시쿼넘, 인코포레이티드 Methods and processes for non-invasive assessment of genetic variations
US20150051088A1 (en) 2013-08-19 2015-02-19 Abbott Molecular Inc. Next-generation sequencing libraries
US9898575B2 (en) 2013-08-21 2018-02-20 Seven Bridges Genomics Inc. Methods and systems for aligning sequences
US9116866B2 (en) 2013-08-21 2015-08-25 Seven Bridges Genomics Inc. Methods and systems for detecting sequence variants
EP3965111A1 (en) 2013-08-30 2022-03-09 Personalis, Inc. Methods and systems for genomic analysis
CN105793859B (en) 2013-09-30 2020-02-28 七桥基因公司 System for detecting sequence variants
WO2015051275A1 (en) 2013-10-03 2015-04-09 Personalis, Inc. Methods for analyzing genotypes
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
EP4258269A3 (en) 2013-10-04 2024-01-10 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP3055427B1 (en) 2013-10-07 2018-09-12 Sequenom, Inc. Methods and processes for non-invasive assessment of chromosome alterations
WO2015058095A1 (en) 2013-10-18 2015-04-23 Seven Bridges Genomics Inc. Methods and systems for quantifying sequence alignment
EP3058332B1 (en) 2013-10-18 2019-08-28 Seven Bridges Genomics Inc. Methods and systems for genotyping genetic samples
US10053736B2 (en) 2013-10-18 2018-08-21 Seven Bridges Genomics Inc. Methods and systems for identifying disease-induced mutations
US10851414B2 (en) 2013-10-18 2020-12-01 Good Start Genetics, Inc. Methods for determining carrier status
WO2015057565A1 (en) 2013-10-18 2015-04-23 Good Start Genetics, Inc. Methods for assessing a genomic region of a subject
WO2015058120A1 (en) 2013-10-18 2015-04-23 Seven Bridges Genomics Inc. Methods and systems for aligning sequences in the presence of repeating elements
US9063914B2 (en) 2013-10-21 2015-06-23 Seven Bridges Genomics Inc. Systems and methods for transcriptome analysis
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
DE202014010499U1 (en) 2013-12-17 2015-10-20 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
WO2015095355A2 (en) 2013-12-17 2015-06-25 The Brigham And Women's Hospital, Inc. Detection of an antibody against a pathogen
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
AU2015204819B2 (en) 2014-01-10 2021-05-06 Seven Bridges Genomics Inc. Systems and methods for use of known alleles in read mapping
WO2015107430A2 (en) 2014-01-16 2015-07-23 Oslo Universitetssykehus Hf Methods and biomarkers for detection and prognosis of cervical cancer
AU2015209079B2 (en) 2014-01-27 2021-07-15 Archerdx, Llc Methods of preparing nucleic acids for sequencing
US9817944B2 (en) 2014-02-11 2017-11-14 Seven Bridges Genomics Inc. Systems and methods for analyzing sequence data
US11053548B2 (en) 2014-05-12 2021-07-06 Good Start Genetics, Inc. Methods for detecting aneuploidy
US10760109B2 (en) 2014-06-06 2020-09-01 The Regents Of The University Of Michigan Compositions and methods for characterizing and diagnosing periodontal disease
ES2888976T3 (en) 2014-06-23 2022-01-10 Massachusetts Gen Hospital Pan-genomic unbiased identification of DSBs assessed by sequencing (GUIDE-Seq.)
EP3161157B1 (en) 2014-06-24 2024-03-27 Bio-Rad Laboratories, Inc. Digital pcr barcoding
WO2016008899A1 (en) 2014-07-15 2016-01-21 Kymab Limited Targeting human pcsk9 for cholesterol treatment
EP3332790A1 (en) 2014-07-15 2018-06-13 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
DE202015009007U1 (en) 2014-07-15 2016-08-19 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
EP3169811A4 (en) 2014-07-17 2017-12-27 Celmatix Inc. Methods and systems for assessing infertility and related pathologies
EP3578668B1 (en) 2014-07-24 2020-12-30 Abbott Molecular Inc. Methods for the detection and analysis of mycobacterium tuberculosis
WO2016019042A1 (en) 2014-07-30 2016-02-04 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016040446A1 (en) 2014-09-10 2016-03-17 Good Start Genetics, Inc. Methods for selectively suppressing non-target sequences
US10429399B2 (en) 2014-09-24 2019-10-01 Good Start Genetics, Inc. Process control for increased robustness of genetic assays
WO2016060910A1 (en) 2014-10-14 2016-04-21 Seven Bridges Genomics Inc. Systems and methods for smart tools in sequence pipelines
EP3212808B1 (en) 2014-10-30 2022-03-02 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
US10000799B2 (en) 2014-11-04 2018-06-19 Boreal Genomics, Inc. Methods of sequencing with linked fragments
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
JP6767978B2 (en) 2014-12-03 2020-10-14 アイソプレキシス コーポレイション Analysis and screening of cell secretion profiles
WO2016112073A1 (en) 2015-01-06 2016-07-14 Good Start Genetics, Inc. Screening for structural variants
US10208339B2 (en) 2015-02-19 2019-02-19 Takara Bio Usa, Inc. Systems and methods for whole genome amplification
WO2016134342A1 (en) 2015-02-20 2016-08-25 Wafergen, Inc. Method for rapid accurate dispensing, visualization and analysis of single cells
WO2016141294A1 (en) 2015-03-05 2016-09-09 Seven Bridges Genomics Inc. Systems and methods for genomic pattern analysis
EP3283627B1 (en) 2015-04-15 2021-12-01 The General Hospital Corporation Lna-based mutant enrichment next-generation sequencing assays
US10275567B2 (en) 2015-05-22 2019-04-30 Seven Bridges Genomics Inc. Systems and methods for haplotyping
EP3322483A4 (en) 2015-07-14 2019-01-02 Abbott Molecular Inc. Compositions and methods for identifying drug resistant tuberculosis
WO2017011538A1 (en) 2015-07-14 2017-01-19 Abbott Molecular Inc. Purification of nucleic acids using copper-titanium oxides
US10793895B2 (en) 2015-08-24 2020-10-06 Seven Bridges Genomics Inc. Systems and methods for epigenetic analysis
US10584380B2 (en) 2015-09-01 2020-03-10 Seven Bridges Genomics Inc. Systems and methods for mitochondrial analysis
US10724110B2 (en) 2015-09-01 2020-07-28 Seven Bridges Genomics Inc. Systems and methods for analyzing viral nucleic acids
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
JP2018530536A (en) 2015-09-11 2018-10-18 ザ ジェネラル ホスピタル コーポレイション Full verification and sequencing of nuclease DSB (FIND-seq)
AU2016331185A1 (en) 2015-09-30 2018-04-26 The General Hospital Corporation Comprehensive in vitro reporting of cleavage events by sequencing (CIRCLE-seq)
US11347704B2 (en) 2015-10-16 2022-05-31 Seven Bridges Genomics Inc. Biological graph or sequence serialization
US20170199960A1 (en) 2016-01-07 2017-07-13 Seven Bridges Genomics Inc. Systems and methods for adaptive local alignment for graph genomes
EP3400298B1 (en) 2016-01-08 2024-03-06 Bio-Rad Laboratories, Inc. Multiple beads per droplet resolution
US10364468B2 (en) 2016-01-13 2019-07-30 Seven Bridges Genomics Inc. Systems and methods for analyzing circulating tumor DNA
CA3012121C (en) 2016-01-22 2023-09-26 Purdue Research Foundation Charged mass labeling system
US10460829B2 (en) 2016-01-26 2019-10-29 Seven Bridges Genomics Inc. Systems and methods for encoding genetic variation for a population
JP6902052B2 (en) 2016-02-08 2021-07-14 アールジーン・インコーポレイテッドRgene, Inc. Multiple ligase compositions, systems, and methods
US10262102B2 (en) 2016-02-24 2019-04-16 Seven Bridges Genomics Inc. Systems and methods for genotyping with graph reference
US20190062827A1 (en) 2016-03-14 2019-02-28 RGENE, Inc. HYPER-THERMOSTABLE LYSINE-MUTANT ssDNA/RNA LIGASES
ES2952832T3 (en) 2016-03-28 2023-11-06 Ncan Genomics Inc Linked Duplex Target Capture
US10961573B2 (en) 2016-03-28 2021-03-30 Boreal Genomics, Inc. Linked duplex target capture
WO2017180871A1 (en) 2016-04-13 2017-10-19 Purdue Research Foundation Systems and methods for isolating a target in an ion trap
EP3458597B1 (en) 2016-05-18 2022-09-07 Roche Diagnostics GmbH Quantitative real time pcr amplification using an electrowetting-based device
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
CN109415727A (en) 2016-06-13 2019-03-01 格里尔公司 The cell-free nucleic acid of mutation is enriched with for the method for cancer detection
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias
WO2018013558A1 (en) 2016-07-12 2018-01-18 Life Technologies Corporation Compositions and methods for detecting nucleic acid regions
WO2018017892A1 (en) 2016-07-21 2018-01-25 Takara Bio Usa, Inc. Multi-z imaging and dispensing with multi-well devices
EP3491560A1 (en) 2016-07-27 2019-06-05 Sequenom, Inc. Genetic copy number alteration classifications
US11543417B2 (en) 2016-08-29 2023-01-03 Oslo Universitetssykehus Hf ChIP-seq assays
US11250931B2 (en) 2016-09-01 2022-02-15 Seven Bridges Genomics Inc. Systems and methods for detecting recombination
AU2017328953B2 (en) 2016-09-15 2023-09-14 Archerdx, Llc Methods of nucleic acid sample preparation for analysis of cell-free DNA
EP3933039A1 (en) 2016-09-15 2022-01-05 ArcherDX, LLC Methods of nucleic acid sample preparation
US10947582B2 (en) 2016-11-02 2021-03-16 Archerdx, Llc Methods of nucleic acid sample preparation for immune repertoire sequencing
WO2018057928A1 (en) 2016-09-23 2018-03-29 Grail, Inc. Methods of preparing and analyzing cell-free nucleic acid sequencing libraries
US20180203974A1 (en) 2016-11-07 2018-07-19 Grail, Inc. Methods of identifying somatic mutational signatures for early cancer detection
DK3538891T3 (en) 2016-11-11 2022-03-28 Isoplexis Corp COMPOSITIONS AND PROCEDURES FOR CONTEMPORARY GENOMIC, TRANSCRIPTOMIC AND PROTEOMIC ANALYSIS OF SINGLE CELLS
WO2018098372A1 (en) 2016-11-22 2018-05-31 IsoPlexis Corporation Systems, devices and methods for cell capture and methods of manufacture thereof
CA3048420A1 (en) 2016-12-09 2018-06-14 Boreal Genomics, Inc. Linked ligation
WO2018111872A1 (en) 2016-12-12 2018-06-21 Grail, Inc. Methods for tagging and amplifying rna template molecules for preparing sequencing libraries
WO2018118971A1 (en) 2016-12-19 2018-06-28 Bio-Rad Laboratories, Inc. Droplet tagging contiguity preserved tagmented dna
US10982351B2 (en) 2016-12-23 2021-04-20 Grail, Inc. Methods for high efficiency library preparation using double-stranded adapters
EP3574424A1 (en) 2017-01-24 2019-12-04 Sequenom, Inc. Methods and processes for assessment of genetic variations
DK3354746T3 (en) 2017-01-30 2019-09-02 Gmi Gregor Mendel Inst Fuer Molekulare Pflanzenbiologie Gmbh NEW SPIKE-IN NUCLEOTIDES FOR NORMALIZING SEQUENCE DATA
US11274344B2 (en) 2017-03-30 2022-03-15 Grail, Inc. Enhanced ligation in sequencing library preparation
US11118222B2 (en) 2017-03-31 2021-09-14 Grail, Inc. Higher target capture efficiency using probe extension
WO2018183942A1 (en) 2017-03-31 2018-10-04 Grail, Inc. Improved library preparation and use thereof for sequencing-based error correction and/or variant identification
CN110892080A (en) 2017-05-12 2020-03-17 美国控股实验室公司 Compositions and methods for detecting diseases associated with exposure to inhaled carcinogens
CN110622005A (en) 2017-05-12 2019-12-27 美国控股实验室公司 Compositions and methods for detecting non-celiac gluten sensitivity
CA3066645A1 (en) 2017-06-08 2018-12-13 The Brigham And Women's Hospital, Inc Methods and compositions for identifying epitopes
EP3642363A1 (en) 2017-06-20 2020-04-29 Bio-Rad Laboratories, Inc. Mda using bead oligonucleotide
WO2019002265A1 (en) 2017-06-26 2019-01-03 Universität Für Bodenkultur Wien Novel biomarkers for detecting senescent cells
EP3545106B1 (en) 2017-08-01 2022-01-19 Helitec Limited Methods of enriching and determining target nucleotide sequences
US20200263170A1 (en) 2017-09-14 2020-08-20 Grail, Inc. Methods for preparing a sequencing library from single-stranded dna
CA3075932A1 (en) 2017-09-20 2019-03-28 Guardant Health, Inc. Methods and systems for differentiating somatic and germline variants
EP4269583A3 (en) 2017-09-28 2024-01-17 Grail, LLC Enrichment of short nucleic acid fragments in sequencing library preparation
EP3691662A4 (en) 2017-10-06 2021-05-12 The University of Chicago Screening of t lymphocytes for cancer-specific antigens
EP4180534A1 (en) 2017-11-02 2023-05-17 Bio-Rad Laboratories, Inc. Transposase-based genomic analysis
WO2019092269A1 (en) 2017-11-13 2019-05-16 F. Hoffmann-La Roche Ag Devices for sample analysis using epitachophoresis
US11414656B2 (en) 2017-12-15 2022-08-16 Grail, Inc. Methods for enriching for duplex reads in sequencing and error correction
WO2019126249A1 (en) 2017-12-20 2019-06-27 Laboratory Corporation Of America Holdings Compositions and methods to detect head and neck cancer
US20190237161A1 (en) 2017-12-22 2019-08-01 Grail, Inc. Error removal using improved library preparation methods
US20190241944A1 (en) 2018-01-31 2019-08-08 Bio-Rad Laboratories, Inc. Methods and compositions for deconvoluting partition barcodes
US11512002B2 (en) 2018-04-18 2022-11-29 University Of Virginia Patent Foundation Silica materials and methods of making thereof
US20210239700A1 (en) 2018-05-04 2021-08-05 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
EP3791190A2 (en) 2018-05-11 2021-03-17 Laboratory Corporation of America Holdings Compositions and methods to detect kidney fibrosis
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
JP2021526791A (en) 2018-06-04 2021-10-11 ガーダント ヘルス, インコーポレイテッド Methods and systems for determining the cellular origin of cell-free nucleic acids
WO2020023420A2 (en) 2018-07-23 2020-01-30 Guardant Health, Inc. Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
WO2020041293A1 (en) 2018-08-20 2020-02-27 Bio-Rad Laboratories, Inc. Nucleotide sequence generation by barcode bead-colocalization in partitions
AU2019331907A1 (en) 2018-08-30 2021-04-08 Guardant Health, Inc. Methods and systems for detecting contamination between samples
CA3109539A1 (en) 2018-08-31 2020-03-05 Guardant Health, Inc. Microsatellite instability detection in cell-free dna
WO2020096691A2 (en) 2018-09-04 2020-05-14 Guardant Health, Inc. Methods and systems for detecting allelic imbalance in cell-free nucleic acid samples
JP7045527B2 (en) 2018-09-20 2022-03-31 ティーエイエムアイアールエヌエイ・ゲーエムベーハー MicroRNA signature for prediction of liver dysfunction
US20210382002A1 (en) 2018-10-12 2021-12-09 Roche Sequencing Solutions, Inc. Detection methods for epitachophoresis workflow automation
JP2022512848A (en) 2018-10-31 2022-02-07 ガーダント ヘルス, インコーポレイテッド Methods, compositions and systems for calibrating epigenetic compartment assays
US11680261B2 (en) 2018-11-15 2023-06-20 Grail, Inc. Needle-based devices and methods for in vivo diagnostics of disease conditions
CA3121923A1 (en) 2018-12-18 2020-06-25 Wenying Pan Methods for detecting disease using analysis of rna
CN113454218A (en) 2018-12-20 2021-09-28 夸登特健康公司 Methods, compositions, and systems for improved recovery of nucleic acid molecules
US11473136B2 (en) 2019-01-03 2022-10-18 Ncan Genomics, Inc. Linked target capture
WO2020142768A1 (en) 2019-01-04 2020-07-09 Northwestern University Storing temporal data into dna
WO2020159584A1 (en) * 2019-01-28 2020-08-06 Abbott Diabetes Care Inc. Analyte sensors and sensing methods for detecting creatinine
CN113661249A (en) 2019-01-31 2021-11-16 夸登特健康公司 Compositions and methods for isolating cell-free DNA
WO2020176659A1 (en) 2019-02-27 2020-09-03 Guardant Health, Inc. Methods and systems for determining the cellular origin of cell-free dna
WO2020229437A1 (en) 2019-05-14 2020-11-19 F. Hoffmann-La Roche Ag Devices and methods for sample analysis
EP3976822A1 (en) 2019-05-31 2022-04-06 Guardant Health, Inc. Methods and systems for improving patient monitoring after surgery
EP3812472B1 (en) 2019-10-21 2022-11-23 Albert-Ludwigs-Universität Freiburg A truly unbiased in vitro assay to profile off-target activity of one or more target-specific programmable nucleases in cells (abnoba-seq)
EP4065725A1 (en) 2019-11-26 2022-10-05 Guardant Health, Inc. Methods, compositions and systems for improving the binding of methylated polynucleotides
WO2021152586A1 (en) 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Methods of analyzing microbiome, immunoglobulin profile and physiological state
WO2021214766A1 (en) 2020-04-21 2021-10-28 Yeda Research And Development Co. Ltd. Methods of diagnosing viral infections and vaccines thereto
WO2021222828A1 (en) 2020-04-30 2021-11-04 Guardant Health, Inc. Methods for sequence determination using partitioned nucleic acids
US20230203592A1 (en) 2020-05-05 2023-06-29 Akershus Universitetssykehus Hf Compositions and methods for characterizing bowel cancer
US20220025468A1 (en) 2020-05-14 2022-01-27 Guardant Health, Inc. Homologous recombination repair deficiency detection
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
EP4189111A1 (en) 2020-07-30 2023-06-07 Guardant Health, Inc. Methods for isolating cell-free dna
EP4205126A1 (en) 2020-08-25 2023-07-05 Guardant Health, Inc. Methods and systems for predicting an origin of a variant
EP4222278A1 (en) 2020-09-30 2023-08-09 Guardant Health, Inc. Compositions and methods for analyzing dna using partitioning and a methylation-dependent nuclease
EP4267757A1 (en) 2020-12-23 2023-11-01 Guardant Health, Inc. Methods and systems for analyzing methylated polynucleotides
WO2022187862A1 (en) 2021-03-05 2022-09-09 Guardant Health, Inc. Methods and related aspects for analyzing molecular response
EP4305200A1 (en) 2021-03-09 2024-01-17 Guardant Health, Inc. Detecting the presence of a tumor based on off-target polynucleotide sequencing data
EP4308723A1 (en) 2021-03-15 2024-01-24 F. Hoffmann-La Roche AG Targeted next-generation sequencing via anchored primer extension
WO2022204321A1 (en) 2021-03-24 2022-09-29 Ambry Genetics Corporation Conservative concurrent evaluation of dna modifications
IL309799A (en) 2021-07-20 2024-02-01 Regeneron Pharma Butyrophilin-like 2 agents for treating inflammatory disorders
EP4253550A1 (en) 2022-04-01 2023-10-04 GenCC GmbH 6 Co. KG Method for the manufacture of a viral system, a vector system or any transport system for cancer-specific crispr complexes
WO2023220602A1 (en) 2022-05-09 2023-11-16 Guardant Health, Inc. Detecting degradation based on strand bias
WO2023218408A1 (en) 2022-05-11 2023-11-16 Freya Biosciences Aps Methods of identifying strains associated with the human female genitourinary tract

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282337B1 (en) * 2006-04-14 2007-10-16 Helicos Biosciences Corporation Methods for increasing accuracy of nucleic acid sequencing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818395B1 (en) * 1999-06-28 2004-11-16 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences
AU7751600A (en) * 1999-10-06 2001-05-10 Amersham Biosciences Corp. Method for detecting mutations using arrayed primer extension

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282337B1 (en) * 2006-04-14 2007-10-16 Helicos Biosciences Corporation Methods for increasing accuracy of nucleic acid sequencing

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119455A1 (en) * 1997-02-12 2002-08-29 Chan Eugene Y. Methods and products for analyzing polymers
US8168380B2 (en) 1997-02-12 2012-05-01 Life Technologies Corporation Methods and products for analyzing polymers
US20070172860A1 (en) * 2000-12-01 2007-07-26 Hardin Susan H Enzymatic nucleic acid synthesis: compositions and methods
US20070172869A1 (en) * 2000-12-01 2007-07-26 Hardin Susan H Enzymatic nucleic acid synthesis: methods for inhibiting pyrophosphorolysis during sequencing synthesis
US20100255464A1 (en) * 2000-12-01 2010-10-07 Hardin Susan H Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US8314216B2 (en) 2000-12-01 2012-11-20 Life Technologies Corporation Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US8648179B2 (en) 2000-12-01 2014-02-11 Life Technologies Corporation Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US9243284B2 (en) 2000-12-01 2016-01-26 Life Technologies Corporation Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US9845500B2 (en) 2000-12-01 2017-12-19 Life Technologies Corporation Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis
US20100235105A1 (en) * 2001-07-09 2010-09-16 Life Technologies Corporation Method for analyzing dynamic detectable events at the single molecule level

Also Published As

Publication number Publication date
EP2007908A4 (en) 2009-04-29
EP2007908A1 (en) 2008-12-31
WO2008016399A1 (en) 2008-02-07
EP2007908B1 (en) 2010-07-21
DE602007007924D1 (en) 2010-09-02
JP2009533060A (en) 2009-09-17
US20070243535A1 (en) 2007-10-18
ATE474938T1 (en) 2010-08-15
US7282337B1 (en) 2007-10-16
CA2649291A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
US7282337B1 (en) Methods for increasing accuracy of nucleic acid sequencing
US20150159210A1 (en) Methods for Increasing Accuracy of Nucleic Acid Sequencing
US20080103058A1 (en) Molecules and methods for nucleic acid sequencing
US7767400B2 (en) Paired-end reads in sequencing by synthesis
US20090305248A1 (en) Methods for increasing accuracy of nucleic acid sequencing
US20070099212A1 (en) Consecutive base single molecule sequencing
US7767805B2 (en) Methods and compositions for sequencing a nucleic acid
US9163053B2 (en) Nucleotide analogs
US20110301042A1 (en) Methods of sample encoding for multiplex analysis of samples by single molecule sequencing
US7994304B2 (en) Methods and compositions for sequencing a nucleic acid
US20070190546A1 (en) Methods and compositions for sequencing a nucleic acid
US20090163366A1 (en) Two-primer sequencing for high-throughput expression analysis
US20070020650A1 (en) Methods for detecting proteins
WO2009097626A2 (en) Paired-end reads in sequencing by synthesis
US20080138804A1 (en) Buffer composition
US20090226906A1 (en) Methods and compositions for reducing nucleotide impurities
US20090226900A1 (en) Methods for Reducing Contaminants in Nucleic Acid Sequencing by Synthesis
WO2009085328A1 (en) Molecules and methods for nucleic acid sequencing
WO2010096532A1 (en) Sequencing small quantities of nucleic acids
WO2009086353A1 (en) Improved two-primer sequencing for high-throughput expression analysis

Legal Events

Date Code Title Description
AS Assignment

Owner name: HELICOS BIOSCIENCES CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HARRIS, TIMOTHY D.;REEL/FRAME:020103/0108

Effective date: 20071107

AS Assignment

Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, MARYLAND

Free format text: SECURITY AGREEMENT;ASSIGNOR:HELICOS BIOSCIENCES CORPORATION;REEL/FRAME:025388/0347

Effective date: 20101116

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: HELICOS BIOSCIENCES CORPORATION, MASSACHUSETTS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION;REEL/FRAME:027549/0565

Effective date: 20120113

AS Assignment

Owner name: COMPLETE GENOMICS, INC., CALIFORNIA

Free format text: LICENSE;ASSIGNOR:FLUIDIGM CORPORATION;REEL/FRAME:030714/0686

Effective date: 20130628

Owner name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC., CALIFORNI

Free format text: LICENSE;ASSIGNOR:FLUIDIGM CORPORATION;REEL/FRAME:030714/0598

Effective date: 20130628

Owner name: ILLUMINA, INC., CALIFORNIA

Free format text: LICENSE;ASSIGNOR:FLUIDIGM CORPORATION;REEL/FRAME:030714/0783

Effective date: 20130628

Owner name: FLUIDIGM CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HELICOS BIOSCIENCES CORPORATION;REEL/FRAME:030714/0546

Effective date: 20130628

Owner name: SEQLL, LLC, MASSACHUSETTS

Free format text: LICENSE;ASSIGNOR:FLUIDIGM CORPORATION;REEL/FRAME:030714/0633

Effective date: 20130628